Pyrimidine derivatives

ABSTRACT

Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of and claims the benefit of U.S.application Ser. No. 09/249,641, filed Feb. 12, 1999 now U.S. Pat. No.6,200,977, which claims the benefit of U.S. application Ser. No.60/075,005 filed Feb. 17, 1998, the disclosure of each beingincorporated by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

The invention described herein was not made with the aid of anyfederally sponsored grants.

FIELD OF THE INVENTION

The field of the invention is in novel substituted pyrimidine compoundsand their use as pharmacologically active agents capable of suppressingand inhibiting viruses (e.g., herpes viruses). The subject compounds andcompositions are particularly useful in treating and suppressing humanCytomegalovirus.

BACKGROUND OF THE INVENTION

Cytomegalovirus (CMV) is a member of the herpes virus family. Otherwell-known members of the herpes virus family include, for example,herpes simplex virus, types I and II, Epstein-Barr virus and varicellazoster virus. These viruses are related taxonomically, but eachmanifests in a clinically distinct manner. In the case of CMV, medicalconditions arising from congenital infection include jaundice,respiratory distress and convulsive seizures which may result in mentalretardation, neurologic disability or death. Infection in adults isfrequently asymptomatic, but may manifest as mononucleosis, hepatitis,pneumonitis or retinitis, particularly in immunocompromised patientssuch as AIDS sufferers, chemotherapy patients, and organ transplantpatients undergoing tissue rejection therapy.

A variety of drugs have been developed to treat herpes virus infections,including naturally occurring proteins and synthetic nucleoside analogs.For example, the natural anti-viral protein interferon has been used inthe treatment of herpes virus infections, as have the nucleoside analogscytosine-arabinoside, adenine-arabinoside, iodoxyuridine and acyclovir,which is presently the treatment of choice for herpes simplex type IIinfection.

Unfortunately, drugs such as acyclovir that have proven sufficientlyeffective to treat infection by certain herpes viruses are notsufficiently effective to treat CMV. Additionally, drugs currently usedto treat CMV infection, such as9-((1,3-dihydroxy-2-propoxy)methyl)guanidine (ganciclovir, DHPG) andphosphonoformic acid (foscarnet), lack the acceptable side effect andsafety profiles of the drugs approved for treatment of other herpesviruses. Moreover, such drugs are ineffective to treat certain strainsof CMV that have acquired drug resistance. Thus, despite advances in thedevelopment of anti-herpes virus drugs, there remains a need fortherapeutic agents effective in treating CMV infection with an increasedsafety margin. The present invention provides such therapeutic agents inthe form of surprisingly effective substituted pyrimidine compounds.

SUMMARY OF THE INVENTION

The present invention provides novel substituted pyrimidine compounds.The compounds have the general formula I:

in which X represents —NR³R⁴, —OR³, —SR³, aryl, alkyl or arylalkyl. Theletter Y represents a covalent bond, —N(R⁶)—, —O—, —S—, —C(═O)— or analkylene group. R¹ and R² are independently selected from hydrogen,alkyl, —O-alkyl, —S-alkyl, aryl, arylalkyl, —O-aryl, —S-aryl, —NO₂,—NR⁷R⁸, —C(O)R⁹, —CO₂R¹⁰, —C(O)NR⁷R⁸ —N(R⁷)C(O)R⁹, —N(R⁷)CO₂R¹¹,—N(R⁹)C(O)NR⁷R⁸, —S(O)_(m)NR⁷R⁸, —S(O)_(n)R⁹, —CN, halogen, and—N(R⁷)S(O)_(m)R¹¹. The groups R³ and R⁴ are independently selected fromhydrogen, alkyl, aryl or arylalkyl, or, when X is —NR³R⁴, R³ and R⁴taken together with the nitrogen atom to which each is attached form a5-, 6- or 7-membered aromatic or nonaromatic ring containing from one tothree heteroatoms in the ring. R⁵ and R⁶ are independently hydrogen,alkyl, aryl or arylalkyl. R⁷ and R⁸ are each independently hydrogen,alkyl, aryl or arylalkyl, or, when attached to the same nitrogen atomcan be combined with the nitrogen atom to form a 4-, 5-, 6-, 7- or8-membered ring containing from one to three heteroatoms in the ring. R⁹and R¹⁰ are independently selected from hydrogen, alkyl, aryl andarylalkyl. R¹¹ is selected from alkyl, aryl and arylalkyl. The subscriptm is an integer of from 1 to 2 and the subscript n is an integer of from1 to 3.

In addition to the above descriptions of R¹ to R¹¹, the formula above ismeant to represent a number of compounds in which a second ring is fusedto the pyrimidine ring. For example, R¹ can be joined to R², R¹ can bejoined to R³, R³ can be joined to N³(the nitrogen atom at the 3-positionof the pyrimidine ring), R⁵ can be joined to N³, R⁵ can be joined toN¹(the nitrogen atom at the 1-position of the pyrimidine ring) or R² canbe joined to N¹ to form a fused 5-, 6-, or 7-membered ring.

Finally, the compounds of the present invention will typically have amolecular weight of from about 150 to about 750. The compounds providedin the above formula are meant to include all pharmaceuticallyacceptable salts thereof.

The compounds of the present invention are useful in therapeutic as wellas prophylactic and diagnostic applications. Still further, thecompounds are useful in the development of additional therapeutic agentsas standards in a variety of assay formats. Accordingly, the presentinvention provides compositions containing the above compounds andpharmaceutically acceptable excipients or diagnostically acceptableexcipients. The invention further provides methods of inhibiting orsuppressing certain viruses, and methods of treating individualsinfected with such viruses, particularly CMV. In addition to treatmentsfor existing conditions, the present invention also provides methods forprophylactic treatments to prevent the onset of viral infection inpatients undergoing, for example, organ transplants.

Other objects, features and advantages of the present invention willbecome apparent to those skilled in the art from the followingdescription and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides the structures of exemplary compounds of formula IIa.

FIG. 2 provides the structures of exemplary compounds of formula IIb.

FIG. 3 provides the structures of exemplary compounds of formula IIc.

FIG. 4 provides the structures of exemplary compounds of formula IId.

FIG. 5 provides the structures of exemplary compounds of formula IIe.

FIGS. 6-14 provide synthesis schemes for exemplary compounds of formulaeIIa-IIe and also selected transformations for functional groups presenton the compounds.

DETAILED DESCRIPTION OF THE INVENTION Abbreviations and Definitions

The term “alkyl,” by itself or as part of another substituent, means,unless otherwise stated, a straight or branched chain or cyclichydrocarbon radical or combinations thereof, which may be fullysaturated, mono- or polyunsaturated and can include di- andmulti-radicals, having the number of carbon atoms designated (i.e.C1-C10 means one to ten carbons). Examples of saturated hydrocarbonradicals include straight or branched chain groups such as methyl,ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl,homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl,n-octyl, and the like. Other saturated hydrocarbon radicals includecyclopropylmethyl, cyclohexylmethyl and the like. An unsaturated alkylgroup is one having one or more double bonds or triple bonds. Examplesof unsaturated alkyl groups include vinyl, 2-propenyl, crotyl,2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl),ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs andisomers. The term “alkyl,” unless otherwise noted, is also meant toinclude those derivatives of alkyl defined below as heteroalkyl,alkylene, heteroalkylene, cycloalkyl and heterocycloalkyl. Typically, analkyl group will have from 1 to 24 carbon atoms, with those groupshaving 10 or fewer carbon atoms being preferred in the presentinvention. The term “alkylene” by itself or as part of anothersubstituent means a divalent radical derived from an alkane, asexemplified by —CH₂CH₂CH₂CH₂—. A “lower alkyl” or “lower alkylene” is ashorter chain alkyl or alkylene group, generally having eight or fewercarbon atoms. Unless otherwise indicated, the alkyl groups can beunsubstituted or substituted by the substituents indicated below.

The term “heteroalkyl,” by itself or in combination with another term,means, unless otherwise stated, a stable straight or branched chainradical consisting of the stated number of carbon atoms and from one tothree heteroatoms selected from the group consisting of O, N, Si and S,and wherein the nitrogen and sulfur atoms may optionally be oxidized andthe nitrogen heteroatom may optionally be quaternized. The heteroatom(s)O, N and S may be placed at any interior position of the heteroalkylgroup. The heteroatom Si may be placed at any position of theheteroalkyl group, including the position at which the alkyl group isattached to the remainder of the molecule. Examples include—CH₂—CH₂—O—CH₃, —CH₂—CH₂—NH—CH₃, —CH₂—CH₂—N(CH₃)—CH₃, —CH₂—S—CH₂—CH₃,—CH₂—CH₂—S(O)—CH₃, —CH₂—CH₂—S(O)₂—CH₃, —CH═CH—O—CH₃, —Si(CH₃)₃,—CH₂—CH═N—OCH₃, and —CH═CH—N(CH₃)—CH₃. Up to two heteroatoms may beconsecutive, such as, for example, —CH₂—NH—OCH₃ and —CH₂—O—Si(CH₃)₃. Theterm “heteroalkylene” by itself or as part of another substituent meansa divalent radical derived from heteroalkyl, as exemplified by—CH₂—CH₂—S—CH₂CH₂— and —CH₂—S—CH₂—CH₂—NH—CH₂—.

The terms “cycloalkyl” and “heterocycloalkyl”, by themselves or incombination with other terms, represent, unless otherwise stated, cyclicversions of “alkyl” and “heteroalkyl”, respectively. Examples ofcycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl,3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkylinclude 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl,3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl,tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl,1-piperazinyl, 2-piperazinyl, and the like.

The terms “halo” or “halogen,” by themselves or as part of anothersubstituent, mean, unless otherwise stated, a fluorine, chlorine,bromine, or iodine atom. Additionally, terms such as “fluoroalkyl,” aremeant to include monofluoroalkyl and polyfluoroalkyl. More particularly,the term “fluoroalkyl” also includes perfluoroalkyl, in which eachhydrogen present in an alkyl group has been replaced by a fluorine.

The term “aryl,” employed alone or in combination with other terms(e.g., aryloxy, arylthioxy, arylalkyl) means, unless otherwise stated,an aromatic substituent which can be a single ring or multiple rings (upto three rings) which are fused together or linked covalently. The ringsmay each contain from zero to four heteroatoms selected from N, O, andS, wherein the nitrogen and sulfur atoms are optionally oxidized, andthe nitrogen atom(s) are optionally quaternized. Non-limiting examplesof aryl groups include phenyl, 1-naphthyl, 2-naphthyl, biphenyl,1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl,4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl,3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl,5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl,3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl,purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl,2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituentsfor each of the above noted aryl ring systems are selected from thegroup of acceptable substituents described below.

As used herein, the term “bicyclic fused aryl-cycloaIkyl” refers tothose groups in which an aryl ring (or rings) is fused to a cycloalkylgroup (including cycloheteroalkyl groups). The group can be attached tothe remainder of the molecule through either an available valence on thearyl portion of the group, or an available valence on the cycloalkylportion of the group. Examples of such bicyclic fused aryl-cycloalkylgroups are: indanyl, benzotetrahydrofuranyl, benzotetrahydropyranyl and1,2,3,4-tetrahydronaphthyl.

Each of the above terms (e.g., “alkyl” and “aryl” and “bicyclic fusedaryl-cycloalkyl”) will typically include both substituted andunsubstituted forms of the indicated radical. Preferred substituents foreach type of radical are provided below. In the case of radicalscontaining both aryl (including heteroaryl) and alkyl (including, forexample, heteroalkyl, cycloalkyl, and cycloheteroalkyl) portions, eachof the portions can be substituted as indicated.

Substituents for the alkyl groups (including those groups often referredto as alkenyl, heteroalkyl, heteroalkenyl, alkynyl, cycloalkyl,heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a varietyof groups selected from: —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halo,—SiR′R″R′″, —OC(O)R′, —CO₂R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′,—NR″—C(O)—OR′, —NH—C(NH₂)═NH, —NR′C(NH₂)═NH, —NH—C(NH₂)═NR′, —S(O)R′,—S(O)₂R′, —S(O)₂NR′R″, —CN and —NO₂ in a number ranging from zero to(2N+1), where N is the total number of carbon atoms in such radical. R′,R″ and R′″ each independently refer to a hydrogen or C1-C10 alkyl group.Preferably, a substituted alkyl group will have from one to sixindependently selected substituents. More preferably, a substitutedalkyl group will have from one to four independently selectedsubstituents. Nevertheless, certain substituted alkyl groups (e.g.,perfluoroalkyl) will have a full 2N+1 substituents (where N is thenumber of carbon atoms in a saturated alkyl group). Examples ofsubstituted alkyl groups include: —C(O)—CH₃, —C(O)CH₂OH,—CH₂—CH(CO₂H)—NH₂ and —Si(CH₃)₂—CH₂—C(O)—NH₂.

Similarly, substituents for the aryl groups are varied and are selectedfrom: -halo, —OR′, —OC(O)R′, —NR′R″, —SR′, —R′, —CN, —NO₂, —CO₂R′,—CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR″—C(O)—OR′, —NH—C(NH₂)═NH,—NR′C(NH₂)═NH, —NH—C(NH₂)═NR′, —S(O)R′, —S(O)₂R′, —S(O)₂NR′R″, —N₃,—CH(Ph)₂, perfluoro(C₁-C4)alkoxy, and perfluoro(C1-C4)alkyl, in a numberranging from zero to the total number of open valences on the aromaticring system; and where R′ and R″ are independently selected fromhydrogen, (C1-C8)alkyl, aryl, aryl-(C1-C4)alkyl, andaryloxy-(C1-C4)alkyl.

Two of the substituents on adjacent atoms of the aryl ring mayoptionally be replaced with a substituent of the formula—T—C(O)—(CH₂)_(s)—U—, wherein T and U are independently —NH—, —O—, —CH₂—or a single bond, and the subscript s is an integer of from 0 to 2.Alternatively, two of the substituents on adjacent atoms of the arylring may optionally be replaced with a substituent of the formula—A—(CH₂)_(p)—B—, wherein A and B are independently —CH₂—, —O—, —NH—,—S—, —S(O)—, —S(O)₂—, —S(O)₂NR′— or a single bond, and p is an integerof from 1 to 3. One or more of the single bonds of the new ring soformed may optionally be replaced with a double bond. Alternatively, twoof the substituents on adjacent atoms of the aryl ring may optionally bereplaced with a substituent of the formula —(CH₂)_(q)—Z—(CH₂)_(r)—,where q and r are independently integers of from 1 to 3, and Z is —O—,—NR′—, —S—, —S(O)—, —S(O)₂—, or —S(O)₂NR′—. The substituent R′ in —NR′—and —S(O)₂NR′— is selected from hydrogen or (C1-C6)alkyl.

As used herein, the term “heteroatom” is meant to include oxygen (O),nitrogen (N), sulfur (S) and silicon (Si).

The term “pharmaceutically acceptable salts” is meant to include saltsof the active compounds which are prepared with relatively nontoxicacids or bases, depending on the particular substituents found on thecompounds described herein. When compounds of the present inventioncontain relatively acidic functionalities, base addition salts can beobtained by contacting the neutral form of such compounds with asufficient amount of the desired base, either neat or in a suitableinert solvent. Examples of pharmaceutically acceptable base additionsalts include sodium, potassium, calcium, ammonium, organic amino, ormagnesium salt, or a similar salt. When compounds of the presentinvention contain relatively basic functionalities, acid addition saltscan be obtained by contacting the neutral form of such compounds with asufficient amount of the desired acid, either neat or in a suitableinert solvent. Examples of pharmaceutically acceptable acid additionsalts include those derived from inorganic acids like hydrochloric,hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,monohydrogensulfuric, hydriodic, or phosphorous acids and the like, aswell as the salts derived from relatively nontoxic organic acids likeacetic, propionic, isobutyric, oxalic, maleic, malonic, benzoic,succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic,p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Alsoincluded are salts of amino acids such as arginate and the like, andsalts of organic acids like glucuronic or galactunoric acids and thelike (see, for example, Berge, S. M., et al, “Pharmaceutical Salts”,Journal of Phannaceutical Science, 1977, 66, 1-19). Certain specificcompounds of the present invention contain both basic and acidicfunctionalities that allow the compounds to be converted into eitherbase or acid addition salts.

The neutral forms of the compounds may be regenerated by contacting thesalt with a base or acid and isolating the parent compound in theconventional manner. The parent form of the compound differs from thevarious salt forms in certain physical properties, such as solubility inpolar solvents, but otherwise the salts are equivalent to the parentform of the compound for the purposes of the present invention.

In addition to salt forms, the present invention provides compoundswhich are in a prodrug form. Prodrugs of the compounds described hereinare those compounds that readily undergo chemical changes underphysiological conditions to provide a compound of formula I.

Certain compounds of the present invention can exist in unsolvated formsas well as solvated forms, including hydrated forms. In general, thesolvated forms are equivalent to unsolvated forms and are intended to beencompassed within the scope of the present invention.

Certain compounds of the present invention possess asymmetric carbonatoms (optical centers) or double bonds; the racemates, diastereomers,geometric isomers and individual isomers are all intended to beencompassed within the scope of the present invention.

The compounds of the present invention may also contain unnaturalproportions of atomic isotopes at one or more of the atoms thatconstitute such compounds. For example, the compounds may beradiolabeled with radioactive isotopes, such as for example tritium(³H), iodine-125 (¹²⁵I) or carbon-14 (¹⁴C). All isotopic variations ofthe compounds of the present invention, whether radioactive or not, areintended to be encompassed within the scope of the present invention.

Embodiments of the Invention

Compounds

In one aspect, the present invention provides compounds of generalformula I:

in which X represents —NR³R⁴, —OR³, —SR³, aryl, alkyl or arylalkyl. Theletter Y represents a covalent bond, —N(R⁶)—, —O—, —S—, —C(═O)— or analkylene radical. Preferably, Y is —N(R⁶)— or —O—, in which R⁶ is asdefined below. More preferably, Y is —N(R⁶)—. For those embodiments inwhich Y is an alkylene radical, the alkylene radical will typically havefrom 1 to 8 carbon atoms in the chain, with alkylene groups having from1 to 3 carbon atoms being preferred.

R¹ and R² are independently selected from hydrogen, alkyl, —O-alkyl,—S-alkyl, aryl, arylalkyl, —O-aryl, —S-aryl, —NO₂, —NR⁷R⁸, —C(O)R⁹,—CO₂R¹⁰, —C(O)NR⁷R⁸—N(R⁷)C(O)R⁹, —N(R⁷)CO₂R¹¹, —N(R⁹)C(O)NR⁷R⁸,—S(O)_(m)NR⁷R⁸, —S(O)_(n)R⁹, —CN, halogen, or —N(R⁷)S(O)_(m)R¹¹, inwhich R⁷, R⁸, R⁹, R¹⁰ and R¹¹ are as defined below.

In one group of preferred embodiments, R¹ is an electron-withdrawinggroup and R² is an electron-donating group. Within this group ofembodiments, R¹ is preferably —NO₂, —S(O)_(m)NR⁷R⁸, —S(O)_(n)R⁹, —CN,halogen, fluoroalkyl, —C(O)R⁹, —CO₂R¹⁰ or —C(O)NR⁷R⁸. More preferably,R¹ is —CF₃, —NO₂, —CN, —S(O)_(m)NR⁷R⁸, or —CO₂R¹⁰, with —NO₂ being themost preferred. The R² group is preferably hydrogen, lower alkyl,—O-alkyl, —S-alkyl, aryl, arylalkyl, —O-aryl or —S-aryl. Morepreferably, R² will be methyl, ethyl, n-propyl, isopropyl, methoxy,ethoxy, propoxy, methoxymethyl, methylthio, ethylthio or propylthio.

In another group of preferred embodiments, R¹ is an electron-donatinggroup and R² is an electron-withdrawing group. Within this group ofembodiments, R¹ is preferably hydrogen, lower alkyl, —O-alkyl, —S-alkyl,aryl, arylalkyl, —O-aryl or —S-aryl. More preferably, R¹ is methyl,ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, methylthio,ethylthio or propylthio. The R² group is preferably —NO₂,—S(O)_(m)NR⁷R⁸, —S(O)_(n)R⁹, —CN, halogen, fluoroalkyl, —C(O)R⁹, —CO₂R¹⁰or —C(O)NR⁷R⁸. More preferably, R² is —CF₃, —NO₂, —CN, —S(O)_(m)NR⁷R⁸ or—CO₂R¹⁰, with —NO₂ being the most preferred.

The groups R³ and R⁴ are independently hydrogen, alkyl, aryl orarylalkyl, or, taken together with the nitrogen atom to which each isattached form, a 5-, 6- or 7-membered ring containing from one to threeheteroatoms in the ring. In one group of preferred embodiments, R³ andR⁴ are combined with the nitrogen atom to which each is attached, toform a 5- or 6-membered ring. The rings defined by R³ and R⁴ and thenitrogen atom can be saturated, unsaturated or aromatic, and can containadditional heteroatoms. Examples of suitable rings include: pyrrolidine,pyrrole, pyrazole, imidazole, imidazoline, thiazoline, piperidine,morpholine, and the like. In certain preferred embodiments, R³ and R⁴are combined with the nitrogen atom to which each is attached to form a5-membered ring containing two nitrogen atoms, preferably an imidazolering, and most preferably a 2-alkylimidazole ring or a 5-alkylimidazolering. Particularly preferred X groups are 2-methylimidazol-1yl,2,4-dimethylimidazol-1yl, 2-ethylimidazol-1yl, 2-propylimidazol-1yl,2-isopropylimidazol-1yl and 5-methylimidazol-1yl.

The R⁵ group is an alkyl, aryl, arylalkyl or bicyclic fusedaryl-cycloalkyl group. Preferred alkyl groups are those having from oneto eight carbon atoms, either substituted or unsubstituted. Preferredaryl groups include substituted or unsubstituted phenyl, pyridyl, ornaphthyl. Preferred arylalkyl groups include substituted andunsubstituted benzyl, phenethyl, pyridylmethyl and pyridylethyl.Particularly preferred R⁵ groups are phenyl, 4-halophenyl, benzyl,n-butyl, propionyl, acetyl and methyl. Other preferred R⁵ groups arethose in which R⁵ is combined with R⁶ and the nitrogen atom to whicheach is attached to form a ring. Still other preferred R⁵ groups(including some of the preferred fused bicyclic aryl-cycloalkyl groups)are selected from:

In the above radicals, and other groups described herein, the wavy lineis used to indicate the point of attachment to the remainder of themolecule.

In one group of particularly preferred embodiments, R⁵ is a radicalselected from the group consisting of:

In another group of particularly preferred embodiments, R⁵ is a radicalselected from the group consisting of:

The above group of radicals is meant to include those radicals having amixture of stereochemistry as well as pure isomers and enantiomers(those having less than about 5% of another diastereomer or enantiomer,more preferably less than about 2% of another isomer, and mostpreferably less than about 1% of another isomer).

The R⁶ group is typically hydrogen, alkyl, aryl or arylalkyl.Preferably, R⁶ is hydrogen, a lower alkyl group having from one to threecarbon atoms, a phenyl ring or a phenylalkyl group, such as, forexample, a benzyl or a phenethyl group. R⁷ and R⁸ are each independentlyhydrogen, alkyl, aryl or arylalkyl, or, taken together with the nitrogenatom to which each is attached, form a 4-, 5-, 6-, 7- or 8-membered ringcontaining from one to three heteroatoms in the ring. Preferably, R⁷ andR⁸ are each independently a (C1-C8)alkyl group, or are combined to forma 5-, 6-, or 7-membered ring. R⁹ and R¹⁰ are independently selected fromhydrogen, alkyl, aryl and arylalkyl. In preferred embodiments, R⁹ andR¹⁰ are independently selected from hydrogen, (C1-C8)alkyl, phenyl andphenyl(C1-C4)alkyl. R¹¹ is alkyl, aryl or arylalkyl, preferably,(C1-C8)alkyl, phenyl and phenyl(C1-C4)alkyl.

In addition to the above descriptions of R¹ to R¹¹, the present formulaabove is meant to represent a number of compounds in which a second ringis fused to the pyrimidine ring, including structures in which one ofthe pyrimidine ring nitrogen atoms is at the ring junction. For thediscussion below and the claims, the nitrogens are individually referredto as follows: N¹ is the nitrogen atom at the 1-position of the ring(which is between the carbon atom bearing —R² and the carbon atombearing —Y—R⁵). N³ is the nitrogen atom at the 3-position of thepyrimidine ring (which is the nitrogen atom between the carbon bearing—Y—R⁵ and the carbon atom bearing —X). Examples of fused rings are thosein which R¹ is joined to R², R¹ is joined to R³, R³ is joined to N³, R⁵is joined to N³, R⁵ is joined to N¹ or R² is joined to N¹ to form afused 5-, 6-, or 7-membered ring. The ring formed by these combinationswill contain 1-3 heteroatoms (e.g., O, N or S) and can be eitheraromatic or nonaromatic. Preferably the additional ring formed is a 5-or 6-membered ring.

When R¹ and R² are combined to form a ring, the combination can bereplaced with a substituent of the formula —T—C(O)—(CH₂)_(s)—U—, whereinT and U are independently selected from —NH—, —O—, —CH₂— or a singlebond, and the subscript s is an integer of from 0 to 2. Alternatively,the R¹ and R² radicals can be replaced with a substituent of the formula—A—(CH₂)_(p)—B—, wherein A and B are independently selected from —CH₂—,—O—, —NH—, —S—, —S(O)—, —S(O)₂—, —S(O)₂NR′— or a single bond, and p isan integer of from 1 to 3. One or more of the single bonds of the newring so formed may optionally be replaced with a double bond.Alternatively, the R¹ and R² radicals can be replaced with a substituentof the formula —(CH₂)_(q)—Z—(CH₂)_(r)—, where q and r are independentlyintegers of from 1 to 3, and Z is —O—, —NR′—, —S—, —S(O)—, —S(O)₂—, or—S(O)₂NR′—. The substituent R′ in —NR′— and —S(O)₂NR′— is selected fromhydrogen or (C1-C6)alkyl.

The subscript m, in the groups above, is an integer of from 1 to 2,preferably 2. The subscript n, in the groups above, is an integer offrom 1 to 3, preferably 2.

Finally, the compounds of the present invention typically have amolecular weight of from about 150 to about 750. The compounds providedin the above formula are meant to include all pharmaceuticallyacceptable salts thereof.

A number of substituent combinations on the pyrimidine ring areparticularly preferred. For example, one group of preferred embodimentshas the formula:

In compounds of general formula IIa, R¹ is preferably —NO₂, —CF₃,—C(O)NR⁷R⁸, —CO₂R¹⁰, —S(O)₂NR⁷R⁸, —S(O)₂R⁹, —C(O)R⁹, —SO₂NH₂, or —CN andR² is preferably an alkyl group having from 1 to 8 carbon atoms. In themost preferred embodiments, the R³ and R⁴ groups are combined to form a5-membered ring which is optionally fused to an aryl group. Examples ofsuitable 5-membered ring groups (and those which are optionally fused toan aryl group) include pyrrolidine, pyrrole, imidazole, pyrazole,benzimidazole, imidazoline, 1,2,4-triazole, 1,2,3-triazole,imidazolidin-2-one, and the like. More preferably, the R³ and R⁴ groupsare combined to form an imidazole ring which is substituted or,optionally, is fused to an aryl group. Preferred substituted (and fused)imidazole rings include, for example, 2-methylimidazole,2-ethylimidazole, 2-isopropylimidazole, 2-aminoimidazole,5-methylimidazole, 5-ethylimidazole, 5-isopropylimidazole,2,5-dimethylimidazole, benzimidazole, and 2-methylbenzimidazole. The R⁵and R⁶ groups are independently selected from hydrogen, alkyl, aryl andarylalkyl, or can be combined with the nitrogen atom to which each isattached to form a ring which is optionally fused to an aryl group. FIG.1 provides exemplary structures of compounds within this preferred groupof embodiments.

Another group of preferred embodiments are represented by the formula:

In this formula, the fused ring containing R¹ and R² is typically aheterocyclic ring in which the —R¹—R²— group is selected from, forexample, —S(O)₂NR′C(O)—, —S(O)₂NR′C(O)NR″—, —NR′S(O)₂NR″C(O)—,—C(O)NR′C(O)—, —NR′C(O)NR″C(O)—, —NR′C(S)NR″C(O)—, —NR′C(S)NR″C(S)—, inwhich R′ and R″ are independently hydrogen or (C1-C8)alkyl. The R³ andR⁴ groups are preferably combined to form a 5-membered ring which isoptionally fused to an aryl group. More preferably, the R³ and R⁴ groupsare combined to form an imidazole ring which is optionally fused to anaryl group. The R⁵ and R⁶ groups are independently selected fromhydrogen, alkyl, aryl and arylalkyl, or can be combined to form a ringwhich is optionally fused to an aryl group. FIG. 2 provides exemplarystructures of compounds within this preferred group of embodiments.

Yet another group of preferred embodiments is represented by theformula:

In this formula, the divalent radical —R¹—R³— is typically an alkylenegroup, —C(O)NR′C(O)—, —C(O)NR′S(O)₂— or —S(O)₂NR′C(O)—, in which R¹ is ahydrogen or lower alkyl group. Preferably, R² and R⁴ will eachindependently be an alkyl group, more preferably a lower alkyl group.The R⁵ and R⁶ groups are independently selected from hydrogen, alkyl,aryl and arylalkyl, or can be combined to form a ring which isoptionally fused to an aryl group. FIG. 3 provides exemplary structuresof compounds within this preferred group of embodiments.

Still another group of preferred embodiments are represented by theformula:

In this formula, the fused ring portion defined by —R²— is typically a(C3-C5)alkylene group, alkyleneamine group (e.g., —NHCH₂CH₂CH₂—,—NHCH₂CH₂—), or a —NR′C(O)CH₂— group, in which R′ is hydrogen or a loweralkyl group. R¹ is typically —NO₂, —S(O)₂NR⁷R⁸, —S(O)₂R⁹, —CN, —CF₃,—C(O)R⁹, —CO₂R¹⁰ or —C(O)NR⁷R⁸. More preferably, R¹ is —NO₂, —CN, —CF₃or —CO₂R¹⁰, with —NO₂ being the most preferred. The R³ and R⁴ groups arepreferably combined to form a 5-membered ring which is optionally fusedto an aryl group. More preferably, the R³ and R⁴ groups are combined toform an imidazole ring which is optionally fused to an aryl group. TheR⁵ and R⁶ groups are independently selected from hydrogen, alkyl, aryland arylalkyl, or can be combined to form a ring which is optionallyfused to an aryl group. The symbol X⁻represents a suitable counterionfor the quartenary nitrogen. Preferred counterions are those which formpharmaceutically acceptable salts. FIG. 4 provides exemplary structuresof compounds within this preferred group of embodiments.

Another group of preferred embodiments are represented by the formula:

In this formula, R¹ is preferably —NO₂, —S(O)₂NR⁷R⁸, —S(O)₂R⁹, —CN,—CF₃, —C(O)R⁹, —CO₂R¹⁰ or —C(O)NR⁷R⁸. More preferably, R¹ is —NO₂, —CN,—CF³ or —CO₂R¹⁰, with —NO₂ being the most preferred. R² is preferably analkyl group having from 1 to 8 carbon atoms. The R³ and R⁴ groups arepreferably combined to form a 5-membered ring which is optionally fusedto an aryl group. More preferably, the R³ and R⁴ groups are combined toform an imidazole ring which is optionally fused to an aryl group. R⁵ ispreferably hydrogen, (C1-C8)alkyl, phenyl, or phenylalkyl. The fusedring portion defined by —R⁶— is typically a (C3-C5)alkylene group or asubstituted alkylene group (e.g., —C(O)CH₂CH₂CH₂—, —C(O)CH₂CH₂—), or a—NR′C(O)CH₂— group, in which R′ is hydrogen or a lower alkyl group. Thesymbol X⁻represents a suitable counterion for the quatemary nitrogen.Preferred counterions are those which form pharmaceutically acceptablesalts. FIG. 5 provides the structures of exemplary compounds of formulaIIe.

Compositions

In another aspect, the invention provides compositions which aresuitable for pharmaceutical or diagnostic use. The compositions comprisecompounds of formula I provided above, in combination with adiagnostically or pharmaceutically acceptable carrier or excipient.

In one embodiment, the invention provides the subject compounds combinedwith a pharmaceutically acceptable excipient such as sterile saline orother medium, water, gelatin, an oil, etc. to form pharmaceuticallyacceptable compositions. The compositions and/or compounds may beadministered alone or in combination with any convenient carrier,diluent, etc. and such administration may be provided in single ormultiple dosages. Useful carriers include solid, semi-solid or liquidmedia including water and non-toxic organic solvents.

In another embodiment, the invention provides the subject compounds inthe form of a pro-drug, which can be metabolically or chemicallyconverted to the subject compound by the recipient host. A wide varietyof pro-drug derivatives are known in the art such as those that rely onhydrolytic cleavage or oxidative activation of the prodrug.

The compositions may be provided in any convenient form, includingtablets, capsules, lozenges, troches, hard candies, powders, sprays,creams, suppositories, etc. As such, the compositions, inpharmaceutically acceptable dosage units or in bulk, may be incorporatedinto a wide variety of containers. For example, dosage units may beincluded in a variety of containers including capsules, pills, etc.

The compositions may be advantageously combined and/or used incombination with other antiviral agents which are either therapeutic orprophylactic agents, and different from the subject compounds. Thecompositions may also be advantageously combined and/or used incombination with agents that treat or induce conditions often associatedwith the viral infections that are sensitive to the present compounds,such as anti-HIV agents or immunosuppressive agents. In many instances,administration in conjunction with the subject compositions enhances theefficacy of such agents. Exemplary antiviral agents include ganciclovir,foscarnet and cidofovir. Exemplary anti-HIV agents include indinavir,ritonavir, AZT, lamivudine and saquinavir. Exemplary immunosuppressiveagents include cyclosporin and FK-506. The compositions may also beadvantageously used as antiviral prophylactic treatment in combinationwith immunosuppressive protocols such as bone-marrow destruction (eitherby radiation or chemotherapy).

Methods of Use

In yet another aspect, the present invention provides novel methods forthe use of the foregoing compounds and compositions. In particular, theinvention provides novel methods for treating or preventing viruses fromthe herpes family, preferably, cytomegalovirus infections. The methodstypically involve administering to a patient an effective formulation ofone or more of the subject compositions.

The invention provides methods of using the subject compounds andcompositions to treat disease or provide medicinal prophylaxis toindividuals who possess a compromised immune system or are expected tosuffer immunosuppressed conditions, such as patients prior to undergoingimmunosuppressive therapy in connection with organ transplantation oranticancer chemotherapy. These methods generally involve administeringto the host an effective amount of the subject compounds orpharmaceutically acceptable compositions.

The compositions and compounds of the invention and the pharmaceuticallyacceptable salts thereof can be administered in any effective way suchas via oral, parenteral or topical routes. Generally, the compounds areadministered in dosages ranging from about 2 mg up to about 2,000 mg perday, although variations will necessarily occur depending on the diseasetarget, the patient, and the route of administration. Preferred dosagesare administered orally in the range of about 0.05 mg/kg to about 20mg/kg, more preferably in the range of about 0.05 mg/kg to about 2mg/kg, most preferably in the range of about 0.05 mg/kg to about 0.2 mgper kg of body weight per day.

Preparation of the Compounds

The compounds of the present invention can be prepared using generalsynthesis schemes such as those outlined in FIGS. 6-14. One of skill inthe art will understand that the syntheses provided below can bemodified to use different starting materials and alternate reagents toaccomplish the desired transformations. Accordingly, the descriptionbelow, the Figures and the reagents are all expressed as non-limitingembodiments.

Briefly, the compounds of formula I, in which Y is —N(R⁶)— can beprepared from a variety of known pyrridinediones. As shown in FIG. 6,the pyrimidine dione (i) can be converted to the correspondingdichloride (ii) by treatment with reagents such as, for example, POCl₃.Treatment of ii with the desired amines (including heterocyclic amines)provides the target compounds, typically as a mixture of isomers (iii).Separation of the isomers can be accomplished by traditional methodssuch as column chromatography or HPLC. Alternatively, ii can behydrolyzed to a mono chloro compound (using, for example, sodiumacetate, acetic acid, water and ethanol) to provide (iv) which upontreatment with a suitable amine, alkoxide or thiolate ion provides (v).Conversion of the 4-hydroxy group to a 4-chloro substituent anddisplacement with a suitably nucleophilic amine provides the targets(vi).

A number of pyrimidinediones are commercially available and can be usedas starting materials for the above transformations, including, forexample, 5-cyano-6-methyl-2,4-pyrimidinedione (vii),6-methyl-2,4-pyrimidinedione-5-carboxamide (x),6-methyl-2,4-pyrimidinedione-5-sulfonic acid (xv) and6-methyl-5-nitro-2,4-pyrimidinedione. Each of these compounds can beconverted to target compounds of formula (IIa) as illustrated in FIG. 7.For example, 5-cyano-6-methyl-2,4-pyrimidinedione (vii) can be convertedto a dichloride (viii) using reagents such as POCl₃, then furtherconverted to target compounds (e.g., ix) upon treatment with aminesR³—NH—R⁴ (e.g., 2-methylimidazole) and R⁵—NH—R⁶ (N-methylbenzylamine).

The carboxamide group of 6-methyl-2,4-pyrimidinedione-5-carboxamide (x)can be hydrolyzed to a carboxylic acid (xi) with aqueous base and thenconverted to an acid chloride (xii) with POCl₃ (forming a trichloride).Stepwise addition of amines or other suitable nucleophiles provides thetarget compounds (e.g., xiv). Similarly, a trichloride (xvi) is formedby treating 6-methyl-2,4-pyrimidinedione-5-sulfonic acid (xv) withchlorinating agents such as POCl₃. Again, the stepwise addition ofamines or other suitable nucleophiles produces the desired targetspecies (xviii).

Yet another method for the preparation of compounds of formula IIa isshown in FIG. 8. Treatment of either a β-ketoester (xix) or anα-methylene ester (xxi) with base (e.g., sodium alkoxide) and anelectrophile (e.g., an alkylating agent, acylating agent, sulfonylatingagent, and the like) provides a suitably derivatized β-ketoester (xx)which can be converted to a pyrimidinone (xxiii) upon treatment with asubstituted guanidine (xxii), typically in acid (acetic acid) withheating. The substituents in the 5- and 6-positions (R¹ and R²,respectively) are determined by the groups present on the derivatizedβ-ketoester. Chlorination of the pyrimidinone to produce (xxiv) andsubsequent treatment with a nucleophilic nitrogen heterocycle (e.g.,imidazole, 2-alkylimidazole, pyrrolidine, piperidine and the like) aswell as other amines provides the target compounds of formula IIa.Substituted guanidines used in this method of preparation can either beobtained from commercial sources or can be prepared by the treatment ofa secondary amine with cyanamide. Additional literature methods for thepreparation of substituted guanidines are known to those of skill in theart.

A number of transformations can be carried out to attach groups to anunsubstituted position on the pyrimidine ring, or to modify existinggroups (see FIG. 9). For example, a 4-chloro substituent (present, forexample, in xxv) can be displaced with ammonia to produce a4-aminopyrimidine (e.g., xxvi). Treatment of the primary amine withsuccinic anhydride provides (xxvii) which upon treatment with aceticanhydride produces the succinimide compound xxviii (FIG. 9A). Exocyclicamino groups can also be acylated using standard acylating agents asshown in FIG. 9B. Metallation reactions can be carried out onpyrimidines which are unsubstituted in the 6-position (FIG. 9C). Forexample, a 5-nitropyrimidine derivative (xxxi) can be catalytically (H₂)or chemically (e.g., Fe/HCl) reduced to a 5-aminopyrimidine derivative(xxxii) which is then protected as a t-butyl carbamate (xxxiii).Treatment of the protected 5-aminopyrimidine derivative with ametallating agent such as sec-butyllithium provides a metallatedintermediate (xxxiv) which can be acylated (xxxv), sulfonylated (xxxvi)or alkylated (xxxvii), as shown. Similarly (see FIG. 9D), the pyrimidinederivative (xxxviii) can be metallated to produce intermediate (xxxix),then acylated (xl), sulfonylated (xli) or alkylated (xlii). Introductionof functional groups at the 5-position can be accomplished using similarmetallation chemistry on, for example, the pyrimidine derivative(xliii), to produce intermediate (xliv) which can be acylated (xlv),sulfonylated (xlvi) and alkylated (xlvii).

FIGS. 10A-10D provides synthesis schemes for several compounds whichfollow the general methods shown in FIGS. 6-8. For example, FIG. 10Aillustrates the preparation of a substituted guanidine (l) from asecondary amine (xlviii) and a chloroimidate (xlix) and the conversionof ethyl cyanoacetate (li) to the ketoester (lii). Condensation of l andlii produces the pyrimidinone (liii) which can be chlorinated to provideliv and then treated with an amine nucleophile (e.g., 2-methylimidazole)to provide the target lv. FIG. 10B illustrates a similar route in whichethyl acetoactate (lvi) is acylated to provide the tricarbonyl compound(lvii). Condensation of lvii with the substituted guanidine (lviii)provides the pyrimidinone (lix) which is converted to the target (lx)using standard protocols. FIG. 10C illustrates methodology in which asulfonamide group is present in the starting material (lxi) and thesubstituted guanidine (lxiii) contains a nitrogen heterocycle.Accordingly, condensation of lxii and xiii provides the pyrimidinone(lxiv) which is converted to the target (lxv) using POCl₃ (or otherchlorinating agents) followed by reaction with an amine nucleophile(e.g., 1,2,4-triazole). Additionally, the general methodology allows thepreparation of compounds having —O—Ar, —S—Ar, —O-alkyl and —S-alkylgroups at the 2-position of the pyrimidine ring (FIG. 10D). For example,treatment of the ketoester (xx) with the substituted guanidine (lxvi)provides the pyrimidinone (lxvii) which can be chlorinated and condensedwith R³—NH—R⁴ to provide lxix. Removal of the protecting groups yieldsthe 2-aminopyrimidine compound (lxx). Diazotization and subsequentchlorination can be carried out using standard procedures to providelxxi. Diplacement of the chloride with either an oxygen-containingnucleophile or a sulfur-containing nucleophile provides the targetcompounds lxxii or lxxiii, respectively.

FIG. 11 illustrates the preparation of several compounds of formula IIb.In one group of embodiments, substituted pyrimidines having asulfonamide at the 5-position and an ester group at the 6-position(Ixxiv) can be saponified to provide lxxv, which is then cyclized withdehydrating agents (e.g., sulfuric acid or acetic anhydride) to thefused heterocycle shown as lxxvi (see FIG. 11A). In other embodiments,diesters (lxxvii) are saponified to the diacid (lxviii) and converted toa mixture of amides (lxxix, by sequential treatment with aceticanhydride and methylamine), which can then be cyclized by treatment witha dehydrating agent (e.g., acetic anhydride) as indicated to provide abicyclic system (lxxx, see FIG. 11B). Yet another fused bicyclic system(lxxxi) can be prepared beginning with ethyl2-oxocyclopentanecarboxylate, using methods outlined above for theconversion of a β-ketoester to a substituted pyrimidine (see FIG. 11C).Still another group of embodiments can be prepared via manipulation ofnitrile and ester substituents (see FIG. 11D). Briefly, ethylcyanoacetate is first condensed with ethyl oxalyl chloride and theresultant product is treated with a substituted guanidine (exemplifiedherein with N,N-diethylguanidine) to provide the substitutedpyrimidinone (lxxii). Treatment of lxxxii with POCl₃ (or otherchlorinating agent) followed by an appropriate amine (e.g., imidazole,2-alkylimidazole, isopropylethylamine, pyrrolidine) provides thesubstituted pyrimidine (lxxxiii). Ester hydrolysis and Curtiusrearrangement (using, for example, diphenylphosphoryl azide) provide theamino nitrile (lxxxiv). Conversion of the nitrile group to an amide byacid hydrolysis, and subsequent treatment with phosgene (or a phosgeneequivalent such as diphosgene or dimethylcarbonate) provides the fusedbicyclic system, lxxxv which can be further converted to lxxxvi ontreatment with strong base (e.g., NaH) and an alkylating agent (e.g.,MeI). Certain intermediates along these synthetic routes can beconverted to other useful derivatives (FIG. 11E). For example, lxxviican be treated with Lawesson's reagent to provide the thioamidelxxxviii, which on treatment with phosgene (or a phosgene equivalent)provides the fused bicyclic system lxxxix. Alternatively, lxxxvii can betreated with sulfuryl chloride in the presence of a tertiary amine baseto provide the fused bicyclic system xc. FIGS. 11F and 11G illustrateother methods of preparing compounds within the scope of formula IIb. InFIG. 11F, a substituted pyrimidine (xci) having a sulfonamide at the5-position and a carboxylic acid at the 6-position is prepared usingmethods analogous to those described above. Curtius rearrangement of thecarboxylic acid group in xci to an amino group provides xcii, which isthen cyclized to xciii, using phosgene or a phosgene equivalent. FIG.11G shows the preparation of a pyrimidine diester (xciv) and itsconversion to the fused bicyclic system xcvii. Briefly, the silyl esterpresent in xciv is hydrolyzed to the acid which is subjected to aCurtius rearrangement to provide xcv. Conversion of the remaining estergroup to an amide can be accomplished using standard procedures toprovide xcvi. Cyclization of xcvi to xcvii can be carried out usingphosgene or a phosgene equivalent.

Compounds of formula IIc can be prepared by methods outlined in FIG. 12.In one group of embodiments (in FIG. 12A), a 4-chloropyrimidinederivative (xcviii, prepared by methods described above), is treatedwith an amine (e.g., allylamine) to provide xcix. The ester group isthen converted to an N-methyl amide (c) upon treatment with methylaminein an alcohol solvent. Cyclization of c to ci occurs upon treatment withphosgene or an equivalent. Similarly, compounds having moreelectronegative groups in the 6-position can be prepared as shown inFIG. 12B. For example, the chloropyrimidine cii can be produced usingmethods outlined above and then converted to the bicyclic compound ciii,using procedures described for xcix. Still other fused systems offormula IIc can be prepared as shown in FIG. 12C. Here, achloropyrimidine derivative (civ) is treated with a primary amine (e.g.,allylamine) to provide an amino moiety at the 4-position of thepyriridine ring. Cyclization of the amino moiety onto a sulfonamide(present at the 5-position) can be accomplished with phosgene or anequivalent to provide the target (cv).

Preparation of compounds of formula IId can be accomplished, in oneembodiment, as outlined in FIG. 13. Briefly, ethyl nitroacetate can becondensed with a mixed anhydride (cvi) to provide a nitroketoester(cvii) which can then be converted to a pyrimidine (cviii) upontreatment with a suitably substituted guanidine. Removal of theprotecting group, followed by treatment with POCl₃ effects chlorinationof the pyrimidine ring and cyclization to form a pyrimidinium salt(cix). Treatment of cix with an amine nucleophile produces the targetcompound (cx). Other compounds in this group can be prepared by startingwith ethyl 3,3,3-trifluoropropionate or ethyl cyanoacetate and varyingboth the substituted guanidine and the amino nucleophile which are used.

Preparation of certain compounds of formula IIe can be accomplishedfollowing procedures outlined in FIG. 14. According to the schemedepicted in FIG. 14, a suitably substituted guanidine (cxi, preparedfrom a protected hydroxypropylamine) is condensed with ethyl2-nitroacetoacetate (or similarly ethyl 2-trifluoromethylacetoacetate)to provide the a pyrimidinone (cxii). Removal of the protecting group,chlorination and cyclization using procedures similar to those shown inFIG. 13, produces the salt (cxiii). Subsequent treatment of cxiii with anucleophilic amine produces the target (cxiv).

The compounds used as initial starting materials in this invention maybe purchased from commercial sources or alternatively are readilysynthesized by standard procedures which are well know to those ofordinary skill in the art.

Some of the compounds of the present invention will exist asstereoisomers, and the invention includes all active stereoisomericforms of these compounds. In the case of optically active isomers, suchcompounds may be obtained from corresponding optically active precursorsusing the procedures described above or by resolving racemic mixtures.The resolution may be carried out using various techniques such aschromatography with a chiral solid support or a chiral solvent, repeatedrecrystallization of derived asymmetric salts, or derivatization, whichtechniques are well known to those of ordinary skill in the art.

The compounds of the invention may be labeled in a variety of ways. Forexample, the compounds may contain radioactive isotopes such as, forexample, ³H (tritium), ¹²⁵I(iodine-125) and ¹⁴C (carbon-14). Similarly,the compounds may be advantageously joined, covalently or noncovalently,directly or through a linker molecule, to a wide variety of othercompounds, which may provide pro-drugs or function as carriers, labels,adjuvents, coactivators, stabilizers, etc. Such labeled and joinedcompounds are contemplated within the present invention.

Analysis of Compounds

The subject compounds and compositions were demonstrated to havepharmacological activity in in vitro and in vivo assays, e.g., they arecapable of specifically modulating a cellular physiology to reduce anassociated pathology or provide or enhance a prophylaxis.

Certain preferred compounds and compositions are capable of specificallyinhibiting or suppressing cytomegalovirus infection. For the assessmentof activity against human CMV, a method was used which is similar tothat described in Kohler, et al., J. Virol. 68:6589-6597 (1994).Briefly, a recombinant human cytomegalovirus (HCMV) was made containinga marker gene (luciferase) under the control of the promoter for thelate 28 kDa viral structural phosphoprotein pp28. Human foreskinfibroblast (HFF) cells were infected with the recombinant HCMV virus(MOI 5), placed into 96-well plates, and cultured under standardcell-culture conditions. Compounds that were evaluated for anti-HCMVactivity were added to the infected cells 1 hour later. The level ofluciferase expression was measured 24 hours after treatment with thetest compounds. The biological activity of the test compounds isdescribed by their IC₅₀ values, the concentration of test compound thatreduces recombinant HCMV late gene expression (represented by luciferaseexpression in the HFF culture) by 50% relative to control(vehicle-treated) infected cells. As an additional control, thecytotoxicity of test compounds on untreated HFF cells was also evaluatedin cultured cell growth experiments.

Table 1 provides biological data for selected compounds from theexamples below.

TABLE 1 Compound IC₅₀ (μM) a 0.8 c 0.1 d 0.02 f 6.0 g 0.8 h 0.3 j 0.01 k1.0 m 2.0 n 0.4 o 2.0 p 0.3 q 3.0 s 3.0 t 10.0 u 0.1

The following examples are offered by way of illustration and not by wayof limitation.

EXAMPLES

¹H-NMR spectra were recorded on a Varian Gemini 400 MHz NMRspectrometer. Significant peaks are tabulated in the order number ofprotons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet;m, multiplet; br s, broad singlet) and coupling constant(s) in Hertz.Electron Ionization (EI) mass spectra were recorded on a Hewlett Packard5989A mass spectrometer. Mass spectrometry results are reported as theratio of mass over charge, followed by the relative abundance of eachion (in parentheses). All reagents, starting materials and intermediatesutilized in these examples are readily available from commercial sourcesor are readily prepared by methods known to those skilled in the art.

Example 1

This example illustrates the synthesis of2-(N-methylanilino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(a) and an isomer4-(N-methylanilino)-2-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(b).

To a stirred cold (−78° C.) solution of2,4-dichloro-6-methyl-5-nitropyrimidine (2.25 g, 10.8 mmol, 1.0 eq) inTHF (15 mL) was added 2-methylimidazole ( 977 mg, 11.9 mmol, 1.1 eq) ina solution of THF (15 mL) dropwise. After 1 hour, the dry ice bath wasreplaced with a water ice bath and stirring was continued for anadditional 2 hours and 15 minutes. At this time N-methylaniline (4.6 mL,43.2 mmol, 4.0 eq) was added. The reaction solution was stirred 1 hourand 15 minutes at −78° C. and at room temperature overnight. At thistime the solvent was removed and the residue was diluted withdichloromethane and washed three times with 0.1M HCl and three timeswith saturated aqueous NaCl solution. The organic phase was evaporatedand the residue was purified by chromatography on silica gel (1:1hexane/diethyl ether, 1% AcOH as eluant) to provide 209 mg of the targetcompound a (6%) along with an isomer (400 mg) and b (104.8 mg).

(a) ¹H NMR (400 MHz) (CD₃OD): δ 2.26 (3H, br s); 2.58 (3H, br s); 3.61(3H, s); 6.88 (1H, s); 7.02 (2H, d); 7.31-7.34 (3H, m); 7.43-7.48 (2H,m). Anal. calcd. for C₁₆H₁₆N₆O₂: C, 59.25; H, 4.97; N, 25.91. Found C,59.16; H, 4.95; N, 25.86.

(b) ¹H NMR (400 MHz) (CDCl₃): δ 2.40 (3H, s); 2.80 (3H, s); 3.55 (3H,s); 6.95 (1H, s); 7.13 (2H, m); 7.30-7.39 (3H, m); 7.86 (2H, s).

Example 2

This example illustrates the synthesis of2-(N-methylanilino)4-(2-methylimidazol-1-yl)-6ethyl-5-nitropyrimidine(c).

To a stirred, cold (−78° C.) solution of a (54.4 mg, 0.168 mmol, 1.0 eq)in THF (1.0 mL) was added LiN(SiMe₃)₂, ( 0.20 mmol, 0.20 mL, of a1.0M/THF solution) dropwise. After stirring for 10 minutes, MeI (0.105mL, 1.68 mmol, 10 eq) was added dropwise. The reaction was kept at −78°C. for 40 minutes and stirred for an additional 4 hours at 0° C. A smallportion of acetic acid (0.25 mL) was poured into the flask and the brownresidue was evaporated to dryness. The residue was then dissolved indichloromethane and washed three times with saturated aqueous NaClsolution and the organic phase was evaporated to dryness to provide acrude yellow oil.

Purification was carried out by column chromatography on silica gel with1:1 hexane/diethyl ether, 1% AcOH, 3% MeOH as eluant, to provide 21.4 mgof the desired product (37%).

(c) ¹H NMR (400 MHz) (CD₃OD): δ 1.29 (3H, br s); 2.28 (3H, br s); 2.86(2H, br s); 3.63 (3H, s); 6.89 (1H, s); 7.02 (1H, s); 7.30-7.39 (3H, m);7.42-7.49 (2H, m). MS ESI m/z (relative intensity): M+H, 339.2 (100);M+Na, 361.1 (15).

Example 3

This example illustrates the synthesis of2-(N-benzyl-N-methylamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(d), 2,4-bis-(N-benzyl-N-methylamino)-6-methyl-5-nitropyrimidine (e) and4-(N-benzyl-N-methylamino)-2-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(f).

To a stirred, cold (−78° C.) solution of2,4-dichloro-6-methyl-5-nitropyrimidine (187.7 mg, 0.9 mmol, 1.0 eq) inTHF (2.25 mL) and EtOH (2.25 mL) was added 2-methylimidazole (148 mg,1.8 mmol, 2.0 eq) in a solution of EtOH (2.25 mL) dropwise. After 45minutes, the dry ice bath was replaced with a water ice bath and themixture was stirred for an additional 2.2 hours. At this timeN-methylbenzylamine (0.465 mL, 3.6 mmol, 4.0 eq) was added. Afterstirring for 2.7 hours, the solvents were removed by evaporation. Theresidue was diluted with dichloromethane and washed three times with0.1M HCl and three times with saturated aqueous NaCl solution. Solventwas removed from the organic phase and the residue was purified bychromatography on silica gel (1:1 hexane/diethyl ether, 1% AcOH, aseluant) to provide d (32 mg), e (116.3 mg) and f (104.8 mg).

(d) ¹H NMR (400 MHz) (CDCl₃): δ 2.30 (1.5H, s); 2.53 (1.5H, s); 2.57(1.5H, s); 2.59 (1.5H, s); 3.15 (1.5H, s); 3.27 (1.5H, s); 4.88 (1H, s);4.97 (1H, s); 6.87 (0.5H, s); 6.90 (0.5H, s); 6.96 (0.5H, s); 6.99(0.5H, s); 7.16 (1H, d); 7.24-7.37 (4H, m). MS ESI m/z (relativeintensity): M+H, 339.2 (100); M+Na, 361.1 (8)

(e) ¹H NMR (400 MHz) (CDCl₃): δ 2.49 (3H, s); 2.79 (3H, s); 2.90-3.20(3H, br m); 4.70-4.88 (4H, br m); 7.12-7.35 (10H, br m). MS ESI m/z(relative intensity): M+H, 378.2 (100); M+Na, 400.1 (15)

(f) ¹H NMR (400 MHz) (CDCl₃): δ 2.52 (3H, s); 2.67 (3H, s); 2.90 (3H,s); 4.92 (2H, s); 6.89 (1H, s); 7.20 (2H, d); 7.28-7.35 (3H, m); 7.74(1H, s). MS ESI m/z (relative intensity): M+H, 339.2 (100).

Example 4

This example illustrates the synthesis of of2-(N-methyl4-chloroanilino)4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(g).

To a stirred, cold (−78° C.) solution of2,4-chloro-6-methyl-5-nitropyrimidine (207.5 mg, 1.0 mmol, 1.0 eq) inTHF (2.25 mL) and EtOH (2.25 mL) was added 2-methylimidazole (164 mg,2.0 mmol, 2.0 eq) in a solution of EtOH (2.25 mL) dropwise. After 45minutes, the dry ice bath was replaced with a water ice bath andstirring was continued for an additional 2.25 hours.4-Chloro-N-methylaniline (0.485 mL, 4.0 mmol, 4.0 eq) was then added andthe reaction solution was stirred for 2.7 hours. Solvent was removed byevaporation and the residue was diluted with dichloromethane, washedthree times with 0.1M HCl, three times with saturated aqueous NaClsolution and dried over MgSO₄. Solvent was removed from the organicphase and the residue was purified by silica gel chromatography (1:1hexane/diethyl ether, 1% AcOH as eluant) to provide g (55.9 mg, 15.6%).

(g) ¹H NMR (400 MHz) (CD₃OD): δ 2.30 (3H, br s); 2.57 (3H, br s); 3.59(3H, s); 6.91 (1H, s); 7.02 (1H, s); 7.36 (2H, d); 7.44 (2H,d). MS ESIm/z (relative intensity): M+H, 359.1 (100).

Example 5

This example illustrates the synthesis of2-(N-methylanilino)4-(2-methylimidazol-1-yl)-6-isopropyl-5-nitropyrimidine(h).

To a stirred, cold (−78° C.) solution of a (38.6 mg, 0.12 mmol, 1.0 eq)in THF (0.5 mL) was added NaH (9.5 mg, 60% in oil 0.24 mmol, 2.0 eq).After stirring for 15 minutes, MeI (0.074 mL, 1.19 mmol, 10 eq) wasadded. The reaction was kept at −78° C. for 2 hours, then stirred anadditional 2.5 hours at 0° C. A small portion of acetic acid (0.25 mL)was poured into the flask and the brown mixture was evaporated todryness. The residue was dissolved into dichloromethane, washed threetimes with water and three times with saturated aqueous NaCl solution.Solvent was removed from the organic phase and the product was purifiedby silica gel chromatography (1:1 hexane/diethyl ether, 1% AcOH aseluant) to provide the target compound (13.3 mg 33%).

(h) ¹H NMR (400 MHz) (CDCl₃): δ 1.20-1.35 (6H, m); 2.29 (3H, br s); 3.24(1H, m); 3.62 (3H, s); 4.92 (2H, s); 6.89 (1H, br s); 7.03 (1H, br s);7.30-7.40 (3H, m); 7.71-7.48 (2H, m). MS ESI m/z (relative intensity):M+H, 353.1 (100).

Example 6

This example illustrates the synthesis of2-(N-benzyl-N-methylamino)-4-(2-methylimidazol-1-yl)-6-ethyl-5-nitropyrimidine(j).

To a stirred, cold (−78° C.) solution of d (57.7 mg, 0.170 mmol in THF(0.5 mL) was added LiN(SiMe₃)₂, (0.17 mL, 0.17 mmol, 1.0 eq, 1.0M/THF)dropwise. After stirring for 10 minutes, MeI (0.106 mL, 1.70 mmol, 10eq) was added dropwise. The reaction was kept at −78° C. for 2 hours andthen stirred for an additional 3 hours at 0° C. A small portion ofacetic acid (0.25 mL) was poured into the flask and the brown mixturewas evaporated to dryness. The residue was dissolved intodichloromethane, washed three times with water, three times withsaturated aqueous NaCl solution and the organic phase was evaporated todryness. The target compound was obtained following silica gelchromatography (1:1 hexane/diethyl ether, 1% AcOH, 3% MeOH as eluant).Yield: 30.3 mg (50.4%).

(j) ¹H NMR (400 MHz) (CD₃OD): δ 1.26-1.41 (3H,m); 2.21 (1.5H,s); 2.45(1.5H, s); 2.86-2.94 (2H, m); 3.22 (1.5H, s); 3.35 (1.5H, s); 4.93 (1H,s); 5.05 (1H,s); 6.91 (0.5H, s); 6.94 (0.5H, s); 7.07 (0.5H, s); 7.12(0.5H, s); 7.23-7.38 (5H, m). MS ESI m/z (relative intensity): M+H,353.1 (100).

Example 7

This example illustrates the synthesis of2-(N,N-diethylamino)-4(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(k).

To a cooled (−78° C.) solution of2,4-dichloro-6-methyl-5-nitropyrimidine (208 mg, 1.0 mmol, 1.0 eq. in 2mL each of EtOH and THF) was added 2-methylimidazole (164 mg, 2.0 mmol,2.0 eq.) in 2 mL of EtOH. The resulting mixture was stirred for 1 hourat −78° C., then for 2 hours at 0° C. Diethylamine (0.413 mL, 4.0 eq.)was added dropwise and the reaction was stirred overnight. The resultingmixture was diluted with dichloromethane, washed with 0.1N HCl,saturated NaCl, dried (MgSO₄), and filtered. Solvent was removed byevaporation and the residue was purified by silica gel chromatography toprovide 35 mg of the target compound k as an oil.

(k) ¹H NMR (400 MHz, CDCl₃): δ 1.15-1.23 (3H, m); 2.48 (3H, s); 2.53(3H, s); 3.59-3.60 (2H, q); 3.68-3.70 (2H, q); 6.86 (1H, s); 6.95 (1H,s). MS ESI m/z (relative intensity): M+H, 291.2 (100).

In a similar manner, the following compounds were prepared using theindicated amine in place of diethylamine. Each was obtained as a yellowoil.

2-(N-benzylbutylamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropylmidineCompound m (N-butylbenzylamine)—40 mg. ¹H NMR (400 MHz, CDCl₃): δ0.86-0.95 (3H, m); 1.23-1.38 (2H, m); 1.51-1.68 (2H, m); 2.52 (3H, m);3.52 (2H, t); 4.83 (1H, s); 6.80 (1H, s); 6.92 (1H, s); 7.13 (2H, d);7.26-7.31 (3H, m). MS ESI m/z relative intensity: M+H, 381.2 (100).

2-(N-methylbutylamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidineCompound n (N-methylbutylamine)—68 mg. ¹H NMR (400 MHz, CDCl₃): δ 0.95(3H, t); 1.32 (2H, m); 2.51 (3H, br s); 2.55 (3H, s); 3.15-3.24 (3H, d);3.58-3.72 (2H, t); 6.85 (1H, s); 6.95 (1H, s). MS ESI m/z (relativeintensity) M+H, 305.4 (100).

2-(N,N-dibenzylamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidineCompound o (Dibenzylamine)—20 mg. ¹H NMR (400 MHz, CDCl₃): 67 2.53 (3H,br s); 2.55 (3H, br s); 4.81 (2H, s); 4.96 (2H,s); 6.85 (1H, s); 6.95(1H, s). MS ESI m/z (relative intensity) M+H, 415.6 (100).

Compound p (4-methylpiperidine)—45 mg. ¹H NMR (400 MHz, CDCl₃): δ1.12-1.16 (3H, m); 2.46 (3H, s); 2.51 (3H, s); 3.40-3.47 (8H, m); 6.84(1H, s); 6.99 (1H, s). MS ESI m/z (relative intensity): M+H, 317.1(100).

Compound q (N-(cyclopropylmethyl)butylamine)—41 mg. ¹H NMR (400 MHz,CDCl₃): δ 0.23-0.64 (4H, m); 0.89-0.93 (3H, m); 1.18 (1H, t); 1.59-1.73(2H, m); 2.49-2.51 (3H, d); 2.54-2.55 (3H, d); 3.46-3.58 (2H, m). MS ESIm/z (relative intensity): M+H, 331.2 (100).

Example 8

This example illustrates the synthesis of2-(N-methylanilino)-4-pyrrolidino-6-methyl-5-nitropyrimidine (r).

To a cooled (−78° C.) solution of2,4-dichloro-6-methyl-5-nitropyrimidine (208 mg, 1.0 mmol, 1.0 eq. in 2mL each of EtOH and THF) is added of pyrrolidine (78 mg, 1.1 eq) in 1.0mL of EtOH. The resulting solution is stirred for 1 hour at −78° C.,then for 2 hours at 0° C. N-methylaniline (0.432 mL, 4.0 eq.) is addeddropwise and the reaction is stirred overnight. The resulting mixture isdiluted with dichloromethane, washed with 0.1N HCl, saturated NaCl,dried (MgSO₄), and filtered. Solvent is removed by evaporation and theresidue is purified by chromatography to provide the target compound(r).

Example 9

This example illustrates the synthesis of2-(N-Methyl-N-benzylamino)4-(2-methylimidazol-1-yl)-5-nitropyrimidine(s).

To a solution of 2,4-dichloro-5-nitropyrimidine (200 mg, 1.0 mmol) indioxane (5 mL) at 80° C. was added 2-methylimidazole (85 mg, 1.0 mmol)and N-methyl-N-benzylamine (133 μL, 1 mmol). The solution was stirredovernight at 80° C., cooled, and directly chromatographed (1/1 hexanediethyl ether) to yield the title compound (s).

(s) ¹H NMR (400 MHz) (CD₃OD): δ 3.09 (s, 1.5H), 3.17 (s, 1.5H), 3.18 (s,1.5H), 4.5-4.8 (m, 2H), 7.2-7.5 (m, 8H).

Example 10

This example illustrates the synthesis of2-(N-Methylanilino)4-(4-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(t).

To a solution of 2,4-dichloro-6-methyl-5-nitropyrimidine (150 mg, 0.72mmol) in dioxane (5 mL) at 80° C. was added 4-methylimidazole (60 mg,0.72 mmol) and N-methylaniline (77 mg, 0.72 mmol). The solution wasstirred overnight at 80° C., cooled, and directly chromatographed (1/1hexane diethyl ether) to yield the title compound (t).

(t) ¹H NMR (400 MHz) (CD₃OD): δ 2.37 (s, 3H), 2.74 (s, 3H), 3.30 (s,3H), 7.25-7.55 (m, 5H), 7.75 (s, 1H), 9.31 (s, 1H).

Example 11

This example illustrates the synthesis of 2-(4-benzylpiperazin-1-yl)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine (u).

To a solution of 2,4-dichloro-6-methyl-5-nitropyrimidine (175 mg, 0.84mmol) in dioxane (5 mL) at 80° C. was added 2-methylimidazole (85 mg,0.84 mmol) and 1-benzylpiperazine (148 μL, 0.84 mmol). The solution wasstirred overnight at 80° C., cooled, and directly chromatographed (1/1hexane diethyl ether) to yield the title compound (u).

(u) ¹H NMR (400 MHz) (CD₃OD): δ 2.42 (s, 3H), 2.60 (s, 3H), 3.38 (br s,4H), 3.80 (br s, 4H), 4.38 (s, 2H), 7.30-7.55 (m, 7H). MS ESI 347 m/e(relative intensity): M+H, 348.0 (100).

Example 12

This example illustrates the synthesis of2-(4-trifluoromethylbenzylamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine(v).

To a stirred mixture of 2-chloro-4-hydroxy-6-methyl-5-nitropyrimidine(300 mg, 1.58 mmol, 1.0 eq) in absolute ethanol (20 mL) was added4-(trifluoromethyl)-benzylamine (540 mg, 3.1 mmol, 2.0 eq), and sodiumacetate (130 mg, 1.58 mmol, 1.0 eq). The mixture was slowly heated andthe resulting solution refluxed for 22 hours. The mixture was thencooled and ethanol was removed in vacuo. The oily residue was dissolvedin ethyl acetate and washed three times with 1M HCl, three times withsaturated NaCl solution, then dried over MgSO₄. Removal of solventprovided a crude yellow solid intermediate which was dried under vacuumthen dissolved in 4 mL of POCl₃ with heating (95-100° C.) for 0.5 hours.The POCl₃ was removed by rotary evaporation and the crude brown productwas purified using chromatography (1:1 hexaneldichloromethane) toprovide a chloropyrimidine intermediate (313 mg), which was carried ondirectly without additional purification.

To a stirred solution of the above chloropyrimidine (150 mg, 0.4 mmol,1.0 eq) in acetonitrile (2.5 mL) was added 2-methylimidazole (142 mg,1.7 mmol, 4.0 eq). The resulting mixture was heated at reflux for 5hours, cooled, and the solvent removed by rotary evaporation. Theresidue was dissolved in ethyl acetate, washed with 0.1M HCl, water,brine and dried over MgSO₄ to give a crude yellow solid followingremoval of solvent. The solid was purified using chromatography with2.5% MeOH/dichloromethane to give a yellow oil. The title compound wasobtained by precipitation from dichloromethane and hexane. Yield: 152.3mg, 51% from the starting 2-chloro-4-hydroxy-6-methyl-5-nitropyrimidine.

(v) ¹H NMR (400 MHz) CDCl₃ δ 2.28 (1.5H, s); 2.42 (1.5H, s); 2.55 (1.5H,s); 2.58 (1.5H, s); 4.71 (1H, d); 4.80 (1H, d); 6.67 (0.5H, br s); 6.80(0.5H,br s); 6.88 (1H, d); 6.96 (1H, s); 7.41 (1H, d); 7.49 (1H, d);7.62 (2H, d). MS ESI m/z (relative intensity): M+H 392.9 (100).

Example 13

This example illustrates the preparation of2-((1-phenyl-1-propyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine(w) using an alternate procedure for the addition of an imidazole groupto the pyrimidine nucleus.

To a stirred solution of2-((1-phenylpropyl)amino)-4-hydroxy-6-methyl-5-nitropyrimidine (78 mg,0.27 mmol, 1.0 eq, prepared in a manner similar to that in Example 12above) in pyridine (1 mL) was added trifluoroacetic anhydride (115 μL,0.81 mmol, 3.0 eq). The mixture was stirred for 15 minutes, thenimidazole (184 mg, 2.7 mmol, 10 eq) was added, and the mixture wasstirred overnight. Pyridine was removed by rotary evaporation and thedark residue was dissolved in ethyl acetate and washed with 0.1M HCl,followed by brine. The crude solid obtained after removal of solvent waspurified by chromatography on silica gel (2.5% MeOH/CH₂Cl₂) to give 36.1mg (42%) of the title compound.

(w) ¹H NMR (400 MHz) CDCl₃ δ 0.99 (3H, m); 1.73-2.02 (2H, m); 2.48 (3H,s); 4.81 (0.66H, dd); 5.07 (0.33H, dd); 6.16 (0.66H, d); 7.02 (0.33H,d); 7.08-7.12 (2H,m); 7.25-7.38 (5H, m); 7.89 (0.66H, s); 8.18 (0.33H,s). MS ESI m/z (relative intensity): M+H 339.2 (100).

Example 14

This example illustrates the synthesis of pyrimidine derivatives havingan alkoxy group in the 2-position, exemplified by2-(1-propyloxy)-4-(2-methylimidazol-1yl)-6-methyl-5-nitropyrimidine (x).

To a flask charged with n-propanol (5 mL) was added NaH (128 mg, 60% inoil 3.19 mmol, 2.0 eq) and the mixture was stirred under nitrogen for 10minutes. The resulting solution was transferred via canula into a flaskcontaining a solution of 2-chloro-4-hydroxy-6-methyl-5-nitropyrimidine(302 mg, 1.6 mmol, 1.0 eq) in n-propanol (5 mL). The resulting mixturewas heated in an oil bath at 100° C. for 1 hour, poured into aseparatory funnel containing dilute HCl and extracted withdichloromethane. The organic phase was separated and washed with water,brine and dried over MgSO₄ to give a crude solid (yield 297 mg) afterremoval of solvent. The crude solid was heated in neat POCl₃ (3 mL) for6 minutes at 85-90° C., cooled on ice, and the POCl₃ was removed invacuo. The chloropyrimidine intermediate was purified via chromatographyto provide 117 mg of the intermediate which was converted to the titlecompound using methods described in Example 12. The product was obtainedas a yellow oil (191 mg, 43% from2-chloro-4-hydroxy-6-methyl-5-nitropymidine).

(x) ¹H NMR (400 MHz) CDCl₃ δ 1.04 (3H, t); 1.86 (2H, dq); 2.52 (3H, s);2.61 (3H, s); 4.38 (2H, t); 6.90 (1H, d); 6.98 (1H, d). MS ESI m/z(relative intensity): M+H 278.1 (100).

Example 15

The compounds listed in Table 2 were prepared using the proceduresoutlined in Examples 12-13. Compounds were tested in the CMV assaydescribed above and exhibited the following levels of activity: +,IC₅₀>500 nM; ++, 100 nM<IC₅₀≦500 nM; +++, IC₅₀≦100 nM.

TABLE 2

Antiviral R^(a) R^(b) R^(c) R^(d) m/z (m + 1) Activity

H Me Me 392.9 ++

H Me Me 353.1 ++

H Et Me 391.1 ++

H Et Me 406.9 ++

H Me Me 377.1 ++

H Et Me 391.1 ++

H Me Me 411.1 ++

H Et Me 425.1 ++

H Me Me 377.1 ++

H Me Me 393.1 ++

H Me Me 411.1 ++

H Me Me 361.1 +++

H Me Me 409.1 ++

H H Me 339.2 +

H H Me 347.1 +

H Me Me 343.1 ++

H Me Me 393.1 ++

H Me Me 359.1 +++

H Me Me 359.1 ++

H Me Me 392.1 +++

H Me Me 339.1 +

H Me Me 359.1 +++

H Me Me 461.1 +

H Me Me 393.1 +++

H Me Me 393.1 ++

H Me Me 339.1 ++

H Me Me 403.0 +++

H Me Me 343.1 ++

H Me Me 355.1 ++

H Me Me 326.1 +

H Me Me 326.1 ++

H Me Me 385.1 ++

H Me Me 379.1 ++

H Me Me 379.1 ++

H Me Me 379.1 ++

H Me Me 379.1 ++

H Me Me 361.1 ++

H Me Me 411.1 +++

H Me Me 373.1 ++

H Me Me 325.1 +

H Me Me 339.1 ++

H Me Me 361.1 ++

Example 16

The compounds listed in Table 3 were prepared using procedures similarto those outlined in Examples 12-14. Compounds were tested in the CMVassay described above and exhibited the following levels of activity: +,IC₅₀>500 nM.

TABLE 3

Antiviral R^(a) R^(b) R^(c) m/z (m + 1) Activity n-propyl Me Me 278.1 +n-propyl H Me 264.1 + n-butyl Me Me 292.2 + n-butyl H Me 278.1 +phenethyl H Me 326.1 + methyl Me Me 250.1 + ethyl Me Me 264.1 + benzyl HMe 312.2 + 3-methoxy-1-butyl H Me 308.1 + 3-methoxy-1-butyl Me Me322.3 + 3,3-dimethyl-1-butyl H Me 306.2 + 3,3-dimethyl-1-butyl Me Me320.1 +

Example 17

This example illustrates the synthesis of2-(2-indanamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine.

2-(2-Indanamino)-4 -chloro-6-methyl-5-nitropyrimidine prepared accordingto the procedure of Example 12, but using 2-indanamine as thenucleophile, (56 mg, 0.18 mmol) was dissolved in 2.0 mL EtOH followed bythe addition of 2-methylimidazole (38 mg, 0.46 mmol, 2.5 equiv). Theresulting yellow solution was placed in an 80° C. bath and allowed tostir for 24 hours. The solution was then concentrated under reducedpressure. Purification by flash chromatography (SiO₂, 2% MeOH/CH₂Cl₂)gave 34 mg of the (52%) title compound as an amorphous yellow: mp203-204° C.

¹H NMR (CDCl₃, 400 MHz, mixture of rotamers) δ 7.28-7.13 (m, 5 H), 6.99(s, 0.5 H), 6.96 (s, 0.5 H), 6.17 (d, J =7.9 Hz, 0.5 H), 6.06 (d, J =7.3Hz, 0.5 H), 4.93 (m, 0.5 H), 4.73 (m, 0.5 H), 3.45-3.34 (m, 2 H), 2.94(dd, J =4.8, 16.2 Hz, 1 H), 2.89 (dd, J =4.3, 16.0 Hz, 1H), 2.71 (s, 1.5H), 2.65 (s, 1.5 H), 2.63, s, 1.5 H), 2.53 (s, 1.5 H); MS ESI m/z(relative intensity): 351.2 (M+H, 100). Anal. calcd for C₁₈H₁₈N₆O₂: C,61.70; H, 5.18; N, 23.99. Found: C, 61.08; H, 5.22; N, 23.57.

Example 18

This example illustrates the synthesis of2-(2-indanamino)-4-imidazol-1-yl-6-methyl-5-nitropyrimidine.

2-(2-Indanamino)-4-chloro-6-methyl-5-nitropyrimidine (66.8 mg, 0.22mmol) was dissolved in 2.0 mL EtOH followed by the addition of imidazole(37 mg, 0.54 mmol, 2.5 equiv). The yellow solution was heated to 80° C.for 18 hours. The solution was then concentrated under reduced pressureand purified by flash chromatography (SiO₂, 2% MeOH/CH₂Cl₂) to give 52.1mg (71%) of the product as an amorphous yellow solid (0.155 mmol): mp177-178° C.

¹H NMR (CDCl₃, 400 MHz, mixture of rotamers) δ 8.23 (s, 0.5 H), 8.16 (s,0.5 H), 7.28-7.11 (m, 6 H), 6.09 (broad s, 0.5 H), 5.91 (d, J =7.2 Hz,0.5 H), 4.93 (m, 0.5 H), 4.79 (m, 0.5 H), 3.40 (dd, J =7.0, 15.9 Hz, 2H), 2.91 (dd, J =4.1, 15.8 Hz, 2 H), 2.56 (s, 1.5 H), 2.46 (s, 1.5 H);); MS ESI(relative abundance) 337.1 (M+H, 100). Anal. calcd forC₁₇H₁₆N₆O₂: C, 60.71; H, 4.79; N, 24.99. Found: C, 60.29; H, 4.89; N,24.69.

Exaple 19

This example illustrates the synthesis of2-(4,6-difluoro-1-indanamino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine.

2-(4,6-Difluoro-1-indanamino)-4-chloro-6-methyl-5-nitropyrimidineprepared according to the procedure of Example 12, using4,6-difluoro-1-indanamine as the nucleophile (56 mg, 0.16 mmol) wasdissolved in 2.0 mL EtOH followed by the addition of imidazole (28 mg,0.411 mmol, 2.5 equiv). The solution was heated to 80° C. for 23 hours.The solution was then concentrated under reduced pressure and purifiedby flash chromatography (SiO₂, 2% MeOH/CH₂Cl₂) to give 35.5 mg (58%yield) of the product as an amorphous yellow solid. mp 175-176° C.

¹H NMR (CDCl₃, 400 MHz, mixture of rotamers) δ 8.09 (s, 0.5 H), 8.06 (s,0.5 H), 7.26-7.10 (m, 2 H), 6.82 (dd, J =7.6, 11.6 Hz, 1H), 6.72 (dd, J=8.8, 8.8 Hz, 1 H), 5.95 (broad s, 0.5 H), 5.82 (d, J =8.4 Hz, 0.5 H),5.72 (m, 0.5 H), 5.56 (m, 0.5 H), 3.05 (m, 1 H), 2.87 (m, 1 H), 2.73 (m,1 H), 2.55 (s, 1.5 H), 2.49 (s, 1.5 H), 1.98 (m, 1 H); ); MSESI(relative abundance) 373.1 (M+H, 100). Anal. calcd for C₁₇H₁₄F₂N₆O₂:C, 54.84; H, 3.79; N, 22.57. Found: C, 54.95; H, 3.76; N, 22.32.

Example 20

This example illustrates the synthesis of2-(4,6-difluoro-1-indanamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine.

2-(4,6-Difluoro-1-indanamino)-4-chloro -6-methyl-5-nitropyrimidine (56mg, 0.16 mmol) was dissolved in 2.0 mL EtOH followed by the addition of2-methylimidazole (34 mg, 0.41 mmol, 2.5 equiv) and the solution washeated to 80° C. with stirring for 26 hours. The solution was thenconcentrated under reduced pressure and purified by flash chromatography(SiO₂, 2% MeOH/CH₂Cl₂) to give 42.6 mg (67% yield) of the as anamorphous yellow solid. mp 164-165° C.

¹H NMR (CDCl₃, 400 MHz, mixture of rotamers) δ 6.98 (s, 1 H), 6.90 (s, 1H), 6.81 (m, 1 H), 6.71 (m, 1 H), 5.87-5.81 (m, 1 H), 5.73 (m, 0.5 H),5.54 (m, 0.5 H), 3.05 (m, 1 H), 2.82 (m, 1 H), 2.70 (m, 1 H), 2.60 (s,1.5 H), 2.53 (s, 1.5 H), 2.51 (s, 1.5 H), 2.46 (s, 1.5 H), 1.98 (m, 1H);); MS ESI (relative abundance) 387.1 (M+H, 100). Anal. calcd forC₁₈H₁₆F₂N₆O₂: C, 55.96; H, 4.17; N, 21.75. Found: C, 56.15; H, 4.59; N,20.71.

Example 21

This example illustrates the synthesis of2-(4,6-difluoro-1-indanamino)-4-(2-ethylimidazol-1-yl)-6-methyl-5-nitropyrimidine.

2-(4,6-Difluoro-1-indanamino)-4-chloro -6-methyl-5-nitropyrimidine (56mg, 0.16 mmol) was dissolved in 2.0 mL EtOH followed by the addition of2-ethylimidazole (39 mg, 0.41 mmol, 2.5 equiv) and the solution washeated to 80° C. for 23.5 hours. The solution was then concentratedunder reduced pressure and purified by flash chromatography (SiO₂, 2%MeOH/CH₂Cl₂) to give 39.6 mg (60% yield) of the product as an amorphousyellow solid: mp 88-89° C.

¹H NMR (CDCl₃, 400 MHz, mixture of rotamers) δ 7.02 (s, 1 H), 6.88 (s, 1H), 6.81 (m, 1 H), 6.72 (m, 1 H), 5.85 (d, J =9.0 Hz, 0.5 H), 5.81-5.70(m, 1 H), 5.55 (m, 0.5 H), 3.04 (m, 1 H), 2.86-2.64 (m, 4 H), 2.60 (s,1.5 H), 2.53 (s, 1.5 H), 1.98 (m, 1 H), 1.29 (t, J =7.5 Hz, 3 H); MSESI(relative abundance): 401.1 (M +H, 100). Anal. calcd forC₁₉H₁₈F₂N₆O₂: C, 57.00; H, 4.53; N, 20.99. Found: C, 56.93; H, 4.50; N,20.71.

Example 22

This example illustrates the synthesis of2-(2-indanamino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine,monohydrochloride salt.

2-(2-Indanamino)-4-chloro-6-methyl-5-nitropyrimidine (310 mg, 1.02 mmol)prepared in Example 17 was dissolved in 7 mL EtOH followed by theaddition of 2-methylimidazole (600 mg, 7.3 mmol, 7.2 equiv). Theresulting yellow solution was then heated at 80° C. with magneticstirring. After 24 hours the solution was concentrated under reducedpressure and purified by flash chromatography (SiO₂, 2% MeOH(CH₂Cl₂) togive 303.6 mg of the free base as a yellow solid (0.867 mmol). Theyellow solid was then dissolved in 3 mL anhydrous THF followed by theaddition of 2 mL (8.0 mmol, 9.2 equiv) of a 4.0 M solution of HCl in1,4-dioxane. A precipitate was immediately formed, and the resultingslurry was allowed to stir for 10 min. The slurry was then concentratedunder reduced pressure, taken up in 3 mL THF, and concentrated again.The resulting yellow solid was recrystallized from hot EtOAc to give 179mg (45% yield) of the hydrochloride salt as light yellow needles: mp184-185° C.

¹H NMR (CD₃OD, 400 MHz, mixture of rotamers) δ 7.76 (d, J =2.2 Hz, 0.5H), 7.71 (d, J =2.2 Hz, 0.5 H), 7.64 (d, J =2.2 Hz, 0.5 H), 7.61 (d, J=2.2 Hz, 0.5 H), 7.22 (m, 2 H), 7.15 (m, 2 H), 4.92 (m, 0.5 H), 4.72 (m,0.5 H), 3.41-3.31 (m, 1 H), 2.97 (m, 1 H), 2.73 (s, 1.5 H), 2.72 (s, 1.5H), 2.68 (s, 1.5 H), 2.65 (s, 1.5 H). Anal. calcd for C₁₈H₁₈N₆O₂.HCl: C,55.89; H, 4.95; N, 21.73; Cl, 9.16. Found: C, 55.89; H, 5.00; N, 21.56;Cl, 9.14.

Example 23

This example illustrates the synthesis of2-(cis-2-ethylcyclohexylamino)-4-imidazol-1-yl-methyl-5-nitropyrimidine.

2-(cis-2-Ethylcyclohexylamino)-4-chloro-6-methyl-5-nitropyrimidine (58.6mg, 0.196 mmol) was dissolved in 2.0 mL ETOH followed by the addition ofimidazole (53 mg, 0.78 mmol, 4.0 equiv). The resulting yellow solutionwas then heated to 80° C. with magnetic stirring. After 20 hours thesolution was concentrated under reduced pressure and purified by flashchromatography (SiO₂, 2% MeOH/CH₂Cl₂) to give 39.5 mg (61% yield) of thetitle compound as an amorphous yellow solid: mp 123-124° C.

¹H NMR (CDCl₃, 400 MHz, mixture of rotamers) δ 8.22 (s, 0.5 H), 8.17 (s,0.5 H), 7.39-7.27 (m, 2 H), 5.92 (d, J =7.8 Hz, 1 H), 4.57 (m, 0.5 H),4.42 (m, 0.5 H), 2.65 (s, 1.5 H), 2.61 (m, 1.5 H), 2.02 (m, 1 H),1.87-1.34 (m, 10 H), 1.02 (t, J =7.0 Hz, 3 H); MS ESI(relativeabundance): 331.2 (M+H, 100). Anal. calcd for C₁₆H₂₂N₆O₂: C, 58.17; H,6.71; N, 25.44. Found: C, 58.01; H, 6.79; N, 25.30.

Example 24

The compounds listed in Table 4 were prepared using the proceduresoutlined in Examples 17-23. Compounds were tested in the CMV assaydescribed above and exhibited the following levels of activity: +,IC₅₀>500 nM; ++, 100 nM<IC₅₀≦500 nM; +++, IC₅₀≦100 nM.

TABLE 4

m/z (m + 1) Antiviral R^(a) R^(b) R^(c) R^(d) or mp (° C.) Activity

H Me Me 351.2 +++

H Me Me 351.2 +++

H Me Me 351.2 +++

H Me Me 365.1 ++

Me Me Me 365.1 ++

H Me Me 385.1 +

Me Me 181-182° C. ++

H Me Me 203-204° C. +

H H Me 177-178° C. +

H Me Me 353.1 ++

H Et Me 88-89° C. ++

H H Me 175-176° C. ++

H Me Me 164-165° C. ++

H H Me 189-190° C. ++

H Et Me 177-178° C. ++

H Me Me 205-206° C. ++

H Et Me 187-188° C. +

H H Me 153-154° C. ++

H Me Me 140-141° C. +++

H Et Me 158-159° C. +++

H H Me 178-179° C. ++

H Me Me 74-75° C. ++

H Et Me 65-66° C. ++

H Me Me 429.1 ++

H H Me 337.1 +++

H Me Me 385.1 ++

H H Me 355.1 +++

H Me Me 369.2 ++

H H Me 367.3 +

H Me Me 381.2 +

H Et Me 365.1 ++

H Me Me 367.3 +++

H Me H 337.1 ++

H H Me 353.1 ++

H H Me 365.1 +

H Me Me 379.2 ++

H Me Me 367.2

H H Me 371.1

H Me Me 385.2

Example 24

The compounds provided in this example were prepared using proceduresoutlined above. The starting materials are available as described above,or from commercial sources.

24.12-(N-(trans-2-methylcyclohexyl)amino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropylmidine

¹H NMR (400 MHz, CDCl₃): δ 0.92(1.5H, d, J=7.2 Hz); 0.94(1.5H, d, J=7.2Hz); 1.00-1.30(5H, m); 1.31-1.41(1H, m); 1.74-1.82(2H, m); 1.94-1.96(1H,m); 2.39(l.5H, s); 2.47(1.5H, s); 2.48(1.5H, s); 2.53(1.5H, s);3.52(0.5H, dq, J=4.0, 9.8 Hz); 3.69(0.5H, dq, J=4.0, 9.8 Hz); 5.86(0.5H,d, J=9.2 Hz), 5.98(0.5H, d, J=9.2 Hz); 6.86(1H, s); 6.93(0.5H, s);6.95(0.5H, s). MS ESI: m/z (relative intensity): M+H, 331.2 (100).

24.22-(N-(cis-2-methylcyclohexyl)amino)-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.93(3H, d, J=7.2 Hz); 1.22-1.41(3H, m);1.48-1.68 (4H, m); 1.71-1.78(1H, m); 1.95(1H, m); 2.44(1.5H, s);2.51(3H, s); 2.57(1.5H, s); 4.13(0.5H, m); 4.28(0.5H, m); 5.68(0.5H, d,J=9.0 Hz), 5.59(0.5H, d, J=9.0 Hz); 6.87(1H, s); 6.94(0.5H, s);6.96(0.5H, s). MS ESI: m/z (relative intensity): M+H, 331.2 (100)

24.32-(N-(trans-2-methylcyclohexyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropymidine

¹H NMR (400 MHz, CDCl₃): δ 0.96(3H, d, J =6.5 Hz); 1.11-1.29(3H, m);1.33-1.39(2H, m); 1.70(1H, m); 1.75-1.83(2H, m) 2.05(1H, dd, J=2.8, 13.4Hz); 2.45(1.5H, s); 2.50(1.5H, s); 3.54(0.5H, dq, J=4.0, 9.8 Hz);3.70(0.5H, dq, J=4.0, 9.8 Hz); 5.43(0.5H, s), 5.46(0.5H, s); 7.12(0.5H,s); 7.15(0.5H, s); 7.17(0.5H, s); 7.18(0.5H, s); 8.04 (0.5H, s);8.08(0.5H, s). MS ESI: m/z (relative intensity): M+H, 317.2 (100).

24.42-(N-(cis-2-methylcyclohexyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.93(3H, d, J=7.2 Hz); 1.22-1.41(3H, m);1.48-1.68 (4H, m); 1.76-1.82(1H, m); 1.94-1.99(1H, m); 2.48(1.5H, s);2.52(1.5H, s); 4.15(0.5H, m); 4.29(0.5H, m); 5.65(0.5H, d, J =7.6 Hz),5.73(0.5H, d, J=7.6 Hz); 7.16(1H, s); 7.21(1H, s); 8.04(0.5H, s);8.10(0.5H, s). MS SEI m/z relative intensity:M+H, 317.2(100)

24.52-(N-(trans-2-methylcyclohexenyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.93(1.5H, d, J=6.8 Hz); 1.00(1.5H, d, J=6.8Hz); 1.22(1H, m); 1.83-1.88(1H, m); 1.93-2.00(1H, m); 2.12(1H, m)2.27(1H, m); 2.44(1.5H, s); 2.49(1.5H, s); 3.93(0.5H, dq, J=1.2, 7.2Hz); 4.08(0.5H, dq J=1.2, 7.2 Hz); 5.51(0.5H, d, J=7.0 Hz), 5.60(1.5H,m); 5.68(0.5H, m); 7.13(1H, s); 7.16(1H, s); 8.00(0.5H, s); 8.07(0.5H,s). MS ESI: m/z (relative intensity): M+H, 315.2 (100).

24.62-(N-(cis-2--methyl-4-cyclohexenyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.96(3H, d, J=6.8 Hz); 1.26(1H, m);1.84-1.92(1H, m); 2.10-2.18(1H, m); 2.27(1H, m) 2.42(1H, m); 2.47(1.5H,s); 2.51(1.5H, s); 4.32(0.5H, m); 4.47(0.5H, m); 5.63(1H, s), 5.72(1H,s); 5.79(0.5H, d, J=9.0 Hz); 5.88(0.5H, d, J=9.0 Hz); 7.13(0.5H, s);7.15(0.5H, s); 7.17(0.5H,s); 7.21(0.5H, s); 8.03(0.5H, s); 8.08(0.5H,s). M ESI: m/z (relative intensity): M+H, 315.2 (100).

24.72-(N-(trans-3-methylcyclohexyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.93(1.5H, d, J=6.5 Hz); 0.96(0.5H, d, J=6.5Hz); 1.01-1.12(1H, m); 1.33-1.41(1H, m); 1.45-1.54(1H, m); 1.60-1.83(5H,m); 2.40(1.5H, s); 2.49(1.5H, s); 2.50(1.5H, s); 2.56(1.5H, s);4.19(0.5H, m); 4.32(0.5H, m); 5.98(0.5H, d, J=6.0 Hz), 6.03(0.5H, d, J=6.0 Hz); 6.88(1H, s); 6.96(1H, s). MS ESI: m/z (relative intensity):M+H, 331.2 (100).

24.82-(N-cis-3-methylcyclohexyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.90(3H, d, J=6.5 Hz); 1.08(1H, m);1.29-1.38(1H, m); 1.42-1.52(1H, m); 1.60-1.70(1H, m); 1.76(1H, m);1.92-2.03(4H, m); 2.36(1.5H, s); 2.46(1.5H, s); 2.49(1.5H, s);2.54(1.5H, s); 3.73(0.5H, m); 3.91(0.5H, m); 6.06(0.5H, bs), 6.22(0.5H,bs); 6.85(1H, s); 6.93(1H, s). MS ESI: m/z (relative intensity): M+H,331.2 (100).

24.92-Cyclohexylamino-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 1.39(2H, m); 1.53(2H, m); 1.74(2H, m);1.90(2H, m); 2.15(2H, m); 2.58(1.5H, s); 2.65(1.5H, s); 2.67(1.5H, s);2.72(1.5H, s); 3.95(0.5H, m); 4.10(0.5H, m); 5.68(0.5H, d, J=4.0 Hz),5.79(0.5H, d, J=4.0 Hz); 7.03(1H, s); 7.12(1H, s). MS ESI: m/z (relativeintensity): M+H, 317.2 (100).

24.102-Cyclohexylmethylamino-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.93-1.03(2H, m); 1.12-1.28(3H, m);1.50-1.61(1H, m); 1.53-1.80(5H, m); 2.44(1.5H, s); 2.50(1.5H, s);3.31(2H, dt, J=6.5, 24 Hz); 5.88(0.5H, bs); 6.40(0.5H, bs); 7.10(0.5H,s); 7.13(1.5H, s), 7.19(0.5H, s); 8.07(1H, s). MS ESI m/z (relativeintensity):M+H, 317.2(100)

24.112-Cyclohexylmethylamino-4-(2-methylimidazol-1-yl)-6-methyl-5-nitopyrimidine

¹H NMR (400 MHz, CDCl₃): δ 0.96(2H, m); 1.14-1.30(4H, m); 1.55(1H, m);1.67(1H, m); 1.67-1.80(5H, m); 2.39(1.5H, s); 2.47(1.5H, s); 2.49(1.5H,s); 2.54(1.5H, s); 3.25(0.5H, t, J=6.3 Hz); 3.35(0.5H, t, J=6.3 Hz);6.02(1H, bs), 6.86(1H, s); 6.95(1H, s). MS ESI m/z (relative intensity):M+H, 331.2 (100).

24.122-Cyclopentylamino-4-(2-methylimidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 1.21(1H, m); 1.49(1H, m); 1.60-1.78(4H, m);2.38(1.5H, s); 2.47(1.5H, s); 2.55(1.5H, s); 4.21(0.5H, m); 4.37(0.5H,m); 5.86(0.5H, d, J=4.2 Hz); 5.98(0.5H, d, J=4.2 Hz); 6.86(1H, s);6.95(1H, s). MS ESI: m/z (relative intensity): M+H, 303.2 (100).

24.132-(N-(4-Methylcyclohexyl)amino)-4-(imidazol-1-yl)-6-methyl-5-nitropyrimidine

¹H NMR (400 MHz, CDCl₃): δ 1.03(1.5H, d, J=6.2 Hz); 1.06(1.5H, d, J=6.2Hz); 1.08(1H, m); 1.15-1.28(1H, m); 1.30-1.42(2H, m); 1.43-1.55(1H, m);1.70-1.84(4H, m); 1.85-1.96(2H, m); 2.18(1H, m); 2.54(1.5H, s); 2.64(3H,s); 2.69(1.5H, s); 3.84(0.5H, m); 4.02(0.5H, m); 5.97(0.5H, bs),6.11(0.5H, bs); 7.01(1H, s); 7.10(1H, s). MS ESI: m/z (relativeintensity): M+H, 331.1 (100).

All publications and patent applications cited in this specification areherein incorporated by reference as if each individual publication orpatent application were specifically and individually indicated to beincorporated by reference. Although the foregoing invention has beendescribed in some detail by way of illustration and example for purposesof clarity of understanding, it will be readily apparent to those ofordinary skill in the art in light of the teachings of this inventionthat certain changes and modifications may be made thereto withoutdeparting from the spirit or scope of the appended claims.

What is claimed is:
 1. A compound having the formula:

wherein X is —NR³R⁴; Y is —N(R⁶)—; R¹ and R² are joined to form a 5-,6-, 7- or 8-membered ring; R³ and R⁴ are taken together with thenitrogen atom to which each is attached form a 5-membered ringcontaining from one to three heteroatoms in the ring; R⁵ is a memberselected from the group consisting of (C₁-C₁₀)alkyl, aryl and arylalkyl;R⁶ is a member selected from the group consisting of hydrogen,(C₁-C₁₀)alkyl, aryl and arylalkyl; or is combined with R⁵ and thenitrogen atom to which R⁵ and R⁶ are attached to form a 5-, 6-, 7- or8-membered ring; m is an integer of from 1 to 2; and said compoundhaving a molecular weight of from about 150 to about
 750. 2. A compoundin accordance with claim 1, wherein R¹ and R² are joined to form a 5- or6-membered ring.
 3. A compound in accordance with claim 2, wherein said5-membered ring formed by R³ and R⁴ contains two nitrogen atoms.
 4. Acompound in accordance with claim 3, wherein said 5-membered ring formedby R³ and R⁴ is an imidazole ring.
 5. A compound in accordance withclaim 4, wherein Y is —N(R⁶)—, in which R⁶ is hydrogen or (C₁-C₈)alkyl.6. A compound in accordance with claim 5, wherein R⁵ is selected fromthe group consisting of cycloalkyl, heterocycloalkyl, aryl andarylalkyl, R⁶ is selected from the group consisting of hydrogen, methyl,ethyl and propyl, and —NR³R⁴ is selected from the group consisting ofimidazol-1-yl, 2-methylimidazol-1yl, 2-ethylimidazol-1-yl,2-(1-propyl)imidazol-1-yl and 2-(2-propyl)imidazol-1-yl.
 7. A compoundin accordance with claim 6, wherein R⁶ is selected from the groupconsisting of hydrogen, methyl and ethyl, —NR³R⁴ is selected from thegroup consisting of imidazol-1-yl, 2-methylimidazol-1yl,2,4-dimethylimidazol-1-yl and 2-ethylimidazol-1-yl, and R⁵ is anoptionally substituted radical selected from the group consisting of


8. A compound in accordance with claim 7, wherein R⁵ is a memberselected from the group consisting of:


9. A compound in accordance with claim 8, said compound being selectedfrom the group consisting of


10. A compound in accordance with claim 8, said compound being selectedfrom the group consisting of


11. A compound in accordance with claim 8, said compound being selectedfrom the group consisting of


12. A compound in accordance with claim 8, said compound being selectedfrom the group consisting of


13. A pharmaceutical composition comprising a pharmaceuticallyacceptable excipient and a compound having the formula:

wherein X is —NR³R⁴; Y is —N(R⁶)—; R¹ and R² are joined to form a 5-,6-, 7- or 8-membered ring; R³ and R⁴ are taken together with thenitrogen atom to which each is attached form a 5-membered ringcontaining from one to three heteroatoms in the ring; R⁵ is a memberselected from the group consisting of(C₁-C₁₀)alkyl, aryl and arylalkyl;R⁶ is a member selected from the group consisting of hydrogen,(C₁-C₁₀)alkyl, aryl and arylalkyl; or is combined with R⁵ and thenitrogen atom to which R⁵ and R⁶ are attached to form a 5-, 6-, 7- or8-membered ring; m is an integer of from 1 to 2; and said compoundhaving a molecular weight of from about 150 to about
 750. 14. Acomposition in accordance with claim 13, wherein R¹ and R² are joined toform a 5- or 6-membered ring.
 15. A composition in accordance with claim14, wherein said 5-membered ring formed by R³ and R⁴ contains twonitrogen atoms.
 16. A composition in accordance with claim 15, whereinsaid 5-membered ring formed by R³ and R⁴ is an imidazole ring.
 17. Acomposition in accordance with claim 16, wherein Y is —N(R⁶)—, in whichR⁶ is hydrogen or (C₁-C₈)alkyl.
 18. A composition in accordance withclaim 17, wherein R⁵ is selected from the group consisting ofcycloalkyl, heterocycloalkyl, aryl and arylalkyl, R⁶ is selected fromthe group consisting of hydrogen, methyl, ethyl and propyl, and —NR³R⁴is selected from the group consisting of imidazol-1-yl,2-methylimidazol-1yl, 2-ethylimidazol-1-yl, 2-(1-propyl)imidazol-1-yland 2-(2-propyl)imidazol-1-yl.
 19. A composition in accordance withclaim 18, wherein R⁶ is selected from the group consisting of hydrogen,methyl and ethyl, —NR³R⁴ is selected from the group consisting ofimidazol-1-yl, 2-methylimidazol-1yl, 2,4-dimethylimidazol-1-yl and2-ethylimidazol-1-yl, and R⁵ is an optionally substituted radicalselected from the group consisting of


20. A composition in accordance with claim 19, wherein R⁵ is a memberselected from the group consisting of:


21. A composition in accordance with claim 20, wherein R⁵ is selectedfrom the group consisting of


22. A composition in accordance with claim 20, wherein R⁵ is selectedfrom the group consisting of


23. A composition in accordance with claim 20, wherein R⁵ is selectedfrom the group consisting of


24. A composition in accordance with claim 20, wherein R⁵ is selectedfrom the group consisting of


25. A method for preventing or treating cytomegalovirus infection in amammal, comprising administering to said mammal a cytomegalovirusinfection inhibiting amount of a compound having the formula:

wherein X is —NR³R⁴; Y is —N(R⁶)—; R¹ and R² are joined to form a 5-,6-, 7- or 8-membered ring; R³ and R⁴ are taken together with thenitrogen atom to which each is attached form a 5-membered ringcontaining from one to three heteroatoms in the ring; R⁵ is a memberselected from the group consisting of (C₁-C₁₀)alkyl, aryl and arylalkyl;R⁶ is a member selected from the group consisting of hydrogen,(C₁-C₁₀)alkyl, aryl and arylalkyl; or is combined with R⁵ and thenitrogen atom to which R⁵ and R⁶ are attached to form a 5-, 6-, 7- or8-membered ring; m is an integer of from 1 to 2; and said compoundhaving a molecular weight of from about 150 to about
 750. 26. A methodin accordance with claim 25, wherein said compound is administered inconjunction with a compound selected from the group consisting ofganciclovir, foscarnet, and cidofovir.
 27. A method in accordance withclaim 25, wherein said compound is administered in conjunction with ananti-HIV compound.
 28. A method in accordance with claim 25, whereinsaid administering is oral.
 29. A method in accordance with claim 25,wherein said administering is topical.
 30. A method in accordance withclaim 25, wherein said administering is prophylactic to prevent theonset of cytomegalovirus infection in patients undergoing organtransplants.
 31. A method in accordance with claim 25, wherein saidadministering is parenteral.
 32. A method in accordance with claim 25,wherein R¹ and R² are joined to form a 5- or 6-membered ring.
 33. Amethod in accordance with claim 32, wherein said 5-membered ring formedby R³ and R⁴ contains two nitrogen atoms.
 34. A method in accordancewith claim 33, wherein said 5-membered ring formed by R³ and R⁴ is animidazole ring.
 35. A method in accordance with claim 34, wherein Y is—N(R⁶)—, in which R⁶ is hydrogen or (C₁-C₈)alkyl.
 36. A method inaccordance with claim 35, wherein R⁵ is selected from the groupconsisting of cycloalkyl, heterocycloalkyl, aryl and arylalkyl, R⁶ isselected from the group consisting of hydrogen, methyl, ethyl andpropyl, and —NR³R⁴ is selected from the group consisting ofimidazol-1-yl, 2-methylimidazol-1yl, 2,4-dimethylimidazol-1-yl,2-ethylimidazol-1-yl, 2-(1-propyl)imidazol-1-yl and2-(2-propyl)imidazol-1-yl.
 37. A method in accordance with claim 36,wherein R⁶ is selected from the group consisting of hydrogen, methyl andethyl, —NR³R⁴ is selected from the group consisting of imidazol-1-yl,2-methylimidazol-1yl, 2,4-dimethylimidazol-1-yl and2-ethylimidazol-1-yl, and R⁵ is an optionally substituted radicalselected from the group consisting of


38. A method in accordance with claim 37, wherein R⁵ is a memberselected from the group consisting of:


39. A method in accordance with claim 38, wherein R⁵ is selected fromthe group consisting of


40. A method in accordance with claim 38, wherein R⁵ is selected fromthe group consisting of


41. A method in accordance with claim 38, wherein R⁵ is selected fromthe group consisting of


42. A method in accordance with claim 38, wherein R⁵ is selected fromthe group consisting of